PF-[ADDRESS_21748] 2020 
PFIZER CONFIDENTIAL
Page 1
A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, 
PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, 
TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 
6 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE ATOPIC 
DERMATITIS OR PLAQUE PSORIASIS
Study Intervention Number: PF-07038124
Study Intervention Name: N/A
US IND Number:
EudraCT Number: 2020-003977-23
Protocol Number: C3941002
Phase: 2a
Short Title: A Phase 2a, randomized, double-blind, vehicle-controlled, parallel group 
study to assess efficacy, safety, tolerability and pharmacokinetics of PF-07038124 ointment in participants with atopic dermatitis or plaque psoriasis
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
promptly notified.
[COMPANY_003]CCI
PF-[ADDRESS_21749] 2020 N/A
[COMPANY_003]
PF-[ADDRESS_21750]: Mechanism of Action ..................272.2.3. Preclinical Safety Data ...............................................................................28
2.3. Benefit/Risk Assessment.........................................................................................31
2.3.1. Risk Assessment .........................................................................................322.3.2. Benefit Assessment.....................................................................................332.3.3. Overall Benefit/Risk Conclusion................................................................[ADDRESS_21751] 2020 
PFIZER CONFIDENTIAL
Page 44.4. End of Study Definition ..........................................................................................42
5. STUDY POPULATION ......................................................................................................42
5.1. Inclusion Criteria.....................................................................................................42
5.1.1. General Inclusion Criteria Applicable for both AD and psoriasis..............425.1.2. Disease-Specific Inclusion Criteria ............................................................43
[IP_ADDRESS]. AD Specific Inclusion Criteria..................................................[IP_ADDRESS]. Psoriasis Specific Inclusion Criteria .........................................43
5.2. Exclusion Criteria....................................................................................................435.3. Lifestyle Cons iderations..........................................................................................46
5.3.1. Contraception..............................................................................................465.3.2. Dietary Supplements...................................................................................465.3.3. Medications/Treatments Discontinuation, Non-Medicated Emollients .....465.3.4. Other Lifestyle Requirements.....................................................................47
5.4. Screen Failures ........................................................................................................48
6. STUDY INTERVENTION..................................................................................................49
6.1. Study Intervention Administered ............................................................................49
6.1.1. Administration ............................................................................................49
[IP_ADDRESS]. Treatable Areas .........................................................................49
6.2. Preparation/Handling/Storage/Accountability ........................................................[ADDRESS_21752] Supplies ........................................53
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................54
6.3.1. Allocation to Study Intervention ................................................................546.3.2. Breaking the Blind......................................................................................54
6.4. Study Intervention Compliance...............................................................................556.5. Concomitant Therapy..............................................................................................55
6.5.1. Rescue Medicine.........................................................................................56
6.6. Dose Modification...................................................................................................566.7. Intervention After the End of the Study..................................................................56
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................[ADDRESS_21753] 2020 
PFIZER CONFIDENTIAL
Page 57.1. Discontinuation of Study Intervention ....................................................................56
7.1.1. Temporary Di scontinuation........................................................................58
7.1.2. Rechallenge.................................................................................................58
7.2. Participant Discontinuation/Withdrawal from the Study........................................[ADDRESS_21754] to Follow-up ....................................................................................................59
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................60
8.1. Efficacy Assessments..............................................................................................61
8.1.1. Rater Qualifications....................................................................................618.1.2. Physician Assessments for AD...................................................................61
[IP_ADDRESS]. Eczema Area and Severity Index (EASI)..................................[IP_ADDRESS]. Investigator’s Global Assessment (IGA) ..................................[IP_ADDRESS]. BSA with AD ............................................................................65
8.1.3. Patient Reported Outcome Measures for AD .............................................65
[IP_ADDRESS]. Peak Pruritus Numerical Rating Scale (PP-NRS) for AD.........66
8.1.4. Physician Assessments for Psoriasis ..........................................................67
[IP_ADDRESS]. Psoriasis Area and Severity Index (PASI) ................................[IP_ADDRESS]. Physician Global Assessment....................................................[IP_ADDRESS]. BSA with Psoriasis....................................................................70
8.1.5. Patient Reported Outcome Measures for Psoriasis.....................................71
[IP_ADDRESS]. Psoriasis Symptom Inve ntory (PSI) for Psoriasis .....................71
8.2. Safety Assessments .................................................................................................72
8.2.1. Medical History ..........................................................................................728.2.2. Physical Examinations (Including Height and Weight) .............................[ADDRESS_21755] 2020 
PFIZER CONFIDENTIAL
Page 68.2.3. Vital Signs ..................................................................................................74
8.2.4. Electrocardiograms.....................................................................................748.2.5. Clinical Safety La boratory Asse ssments ....................................................75
8.2.6. Suicidal Ideation and Behavior Risk Monitoring - Columbia Suicide 
Severity Rating Scale (C-SSRS)......................................................................75
8.2.7. Local Tolerability  Assessment ...................................................................76
8.2.8. Pregnancy Testing ......................................................................................76
8.3. Adverse Events and Serious Adverse Events..........................................................77
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......77
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................78
8.3.2. Method of Detecting AEs and SAEs ..........................................................788.3.3. Follow-up of AEs and SAEs.......................................................................788.3.4. Regulatory Reporting Requirements for SAEs...........................................798.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................79
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................81
8.3.6. Cardiovascular and Death Events...............................................................818.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_21756].............................................................82
[IP_ADDRESS]. Lack of Efficacy........................................................................[ADDRESS_21757] 2020 
PFIZER CONFIDENTIAL
Page 78.9. Immunogenicity Assessments .................................................................................86
8.10. Health Economics .................................................................................................86
9. STATISTICAL C ONSIDERATIONS ................................................................................86
9.1. Estimands and Statistical Hypotheses .....................................................................87
9.1.1. Estimands for AD .......................................................................................879.1.2. Estimands for Psoriasis...............................................................................87
9.2. Sample Size Determination.....................................................................................88
9.2.1. Sample Size Determination for AD............................................................889.2.2. Sample Size Determination for Psoriasis ...................................................88
9.3. Analysis Sets ...........................................................................................................899.4. Statistical Analyses .................................................................................................89
9.4.1. Efficacy Analyses for AD...........................................................................899.4.2. Efficacy Analyses for Psoriasis ..................................................................909.4.3. Safety Analys es ..........................................................................................91
[IP_ADDRESS]. Electrocardiogram Analyses......................................................92
9.5. Interim Analyses .....................................................................................................92
9.6. Data Monitoring Committee or Other Independent Oversight Committee.............92
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................93
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............[ADDRESS_21758] 2020 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................93
10.1.2. Financial Disclosure .................................................................................9410.1.3. Informed Consent Process ........................................................................9410.1.4. Data Protection .........................................................................................9510.1.5. Dissemination of Clinical Study Data ......................................................9510.1.6. Data Qualit y Assurance ............................................................................97
10.1.7. Source Documents....................................................................................9810.1.8. Study and Site Start and Closure ..............................................................9810.1.9. Publication Policy.....................................................................................9910.1.10. Sponsor’s Qualified Medical Personnel ...............................................100
10.2. Appendix 2: Clinical Laboratory Tests ...............................................................[ZIP_CODE].3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ....................................................................102
10.3.1. Definition of AE .....................................................................................[ZIP_CODE].3.2. Definition of SAE...................................................................................[ZIP_CODE].3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.....................[ZIP_CODE].3.4. Reporting of SAEs..................................................................................108
10.4. Appendix 4: Contraceptive Guidance .................................................................109
10.4.1. Male Participant Reproductive Inclusion Criteria ..................................[ZIP_CODE].4.2. Female Participant Reproductive Inclusion Criteria...............................[ZIP_CODE].4.3. Woman of Childbearing Potential ..........................................................[ZIP_CODE].4.4. Contraception Methods...........................................................................110
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments 
and Study Intervention Rechallenge Guidelines .....................................................113
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................[ZIP_CODE].8. Appendix 8: Country-Specific Requirements .....................................................[ZIP_CODE].9. Appendix 9: Alternative Measures During Public Emergencies ........................118
10.9.1. Telehealth Visits .....................................................................................[ZIP_CODE].9.2. Alternative Facilities for Safety Assessments ........................................119
[IP_ADDRESS]. Laboratory Testing ................................................................[ADDRESS_21759] 2020 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Electrocardiograms................................................................119
10.9.3. Study Intervention ..................................................................................[ZIP_CODE].9.4. Home Health Visits.................................................................................[ZIP_CODE].9.5. Adverse Events and Serious Adverse Events .........................................[ZIP_CODE].9.6. Efficacy Assessments .............................................................................[ZIP_CODE].9.7. Independent Oversight Committees .......................................................121
10.10. Appendix 10: Prohibited Prior and Concomitant Medications .........................122
10.10.1. Prohibited Prior and Concomitant Medications ...................................[ZIP_CODE].10.2. Prohibited Concomitant Medications which may result in Drug-
Drug Interaction (DDI) ..................................................................................124
10.11. Appendix 11: Diagnosis Criteria for AD ..........................................................[ZIP_CODE].12. Appendix 12: Abbreviations .............................................................................[ADDRESS_21760] OF TABLES
Table 1. Study Intervention Groups........................................................................15
Table 4. Proposed Doses, Predicted Free Exposures, and Safety Margins 
following QD Topi[INVESTIGATOR_22723]-07038124
a...............................41
Table 5. Clinical Sign Severity Scoring Criteria for EASI.....................................62Table 6. Handprint Determination of Body Region Surface Area for AD .............63Table 7. EASI Area Score Criteria .........................................................................63Table 8. EASI Body Re gion Weighting .................................................................63
Table 9. Investigator’s Global Assessment (IGA) Score........................................64Table 10. Component Scoring Criteria for PASI*....................................................68Table 11. Handprint Determination of Body Region Surface Area for 
Psoriasis ....................................................................................................68
Table 12. PASI Area Score Criteria..........................................................................69
Table 13. PASI Body Region Weighting..................................................................69
Table 14. Physician Global Assessment (PGA) Score .............................................[ADDRESS_21761] 2020 
PFIZER CONFIDENTIAL
Page 111. PROTOCOL SUMMARY 
1.1. Synopsis Short Title: A Phase 2a, randomized, double blind, vehicle controlled, parallel group study 
to assess efficacy, safety, tolerability and pharmacokinetics of PF-07038124 ointment in participants with atopic dermatitis (AD) or plaque psoriasis.
Rationale: This multicenter, randomized, double blind, vehicle controlled, parallel group, 
study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-[ADDRESS_21762] study where PF-07038124 ointment is being administered to participants with AD or psoriasis. 
Objectives, Estimands, and Endpoints
ATOPIC DERMATITIS
Objectives Endpoints Estimands
Primary Objective Primary Endpoint(s) Primary Estimands 
•To compare the efficacy of 
PF-07038124 versus vehicle on percent change from baseline in Eczema
Area and Severity Index 
(EASI) in participants with mild or moderate atopic dermatitis (AD).•Percent change from baseline in 
EASI total score at Week 6.•Estimand E1: This 
estimand is intended to provide a population level estimate of the treatment 
effect of the investigational 
product (IP) on a continuous endpoint; without the benefit of additional prohibited 
medications during 
treatment and regardless of participant compliance with the IP dosing.
Secondary Objective(s): Secondary Endpoints Secondary Estimands 
•To compare the efficacy of 
PF-07038124 versus  vehicle, 
using Investigator’s Global Assessment (IGA) score assessment as endpoint in participants with mild or moderate AD.•Proportion of participants 
achieving IGA score of clear (0) or almost clear (1) (on a 5-pointscale) and a reduction from baseline of ≥2 points at Week 6.•Estimand E2: This estimand 
is intended to provide a population level estimate of the treatment effect of the IP on a binary responder endpoint; without the 
benefit of additional 
prohibited medications and regardless of a participant compliance with the IP dosing.
[COMPANY_003]
PF-[ADDRESS_21763] 2020 
PFIZER CONFIDENTIAL
Page 12ATOPIC DERMATITIS
Objectives Endpoints Estimands
•To compare the efficacy of 
PF-07038124 versus vehicle, using measures of disease severity and symptoms as endpoints in participants with mild or moderate AD.•Proportion of participants 
achieving EASI 75 (75% improvement from baseline)at study visit time points specified in the SoA.•Estimand E2: This estimand 
is intended to provide a population level estimate of the treatment effect of the IP on a binary responder endpoint; without the 
benefit of additional 
prohibited medications and regardless of a participant.
•To compare the efficacy of 
PF-07038124 versus vehicle, 
using measures of patient 
reported outcomes (PRO), in participants with mild or moderate AD.•Proportion of participants having 
≥4 points of reduction in weekly 
averages of Peak Pruritus 
Numerical Rating Scale (PP-NRS) from baseline at study visit time points specified in the SoA.•Estimand E2: This estimand 
is intended to provide a 
population level estimate of 
the treatment effect of the IP on a binary responder endpoint; without the benefit of additional prohibited medications and regardless of a participant.
•To compare the efficacy of 
PF-07038124 versus vehicle, on measures of disease and symptom severity in 
participants with mild or 
moderate AD.•Change from baseline in EASI 
total score at study visit time points specified in the SoA.
•Proportion of participants 
achieving IGA score of clear (0) or 
almost clear (1) at study visit timepoints specified in the SoA.
•Percent change from baseline in 
body surface area (BSA) at study visit time points specified in the SoA.•All continuous secondary 
endpoints will be analyzed descriptively and using estimand E1 described above, when appropriate.
•All categorical secondary 
endpoints will be analyzed descriptively and using estimand E2 described above, when appropriate.
•To characterize the safety 
and tolerability of PF-07038124 vers us vehicle 
in participants with mild or moderate AD.  •Incidence of treatment emergent 
adverse events (AEs) and serious adverse events (SAEs), clinically significant changes in vital signs, 
electrocardiogram (ECG), and 
laboratory tests.
•Incidence of severity grades in skin
tolerability at study visit time points specified in the SoA.•There is no defined 
estimand for these endpoints and they will be analyzed using [COMPANY_007] data standards as applicable.
[COMPANY_003]CCI
PF-[ADDRESS_21764] 2020 
PFIZER CONFIDENTIAL
Page 13PSORIASIS
Objectives Endpoints Estimands
Primary: Primary: Primary:
•To compare the efficacy of 
PF-07038124 vers us vehicle 
on change from baseline in Psoriasis Area and Severity 
Index (PASI) score in 
participants with mild to moderate plaque psoriasis. • Change from baseline in 
PASI score at Week 6.•Estimand E1: This estimand is 
intended to provide a population level estimate of the treatment effect of the investigational 
product (IP) alone on a 
continuous endpoint; without the benefit of additional prohibited medications, regardless of participants compliance with the IP dosing.
Secondary: Secondary: Secondary:
•To compare the efficacy of 
PF-07038124 vers us vehicle 
on Physician GlobalAssessment (PGA) score in 
participants with mild to 
moderate plaque psoriasis.•Proportion of participants 
with PGA score of clear (0) or almost clear (1) (on a 5-point scale) and ≥2 points 
improvement from baseline 
at Week 6. •Estimand E2: This estimand is 
intended to provide a population level estimate of the treatment effect of the IP alone 
on a binary responder 
endpoint; without the benefit of additional prohibited medications, regardless of participants compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 vers us vehicle 
on the proportion of participants with mild to 
moderate plaque psoriasis 
achieving PASI 75. •Proportion of participants 
achieving PASI 75 (75% or greater improvement from baseline) at study visit time points specified in the SoA.•Estimand E2: This estimand is 
intended to provide a population level estimate of the treatment effect of the IP alone 
on a binary responder 
endpoint; without the benefit of additional prohibited medications, regardless of participants compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 versus vehicle, using measures of patient reported outcomes (PRO), in participants with 
mild or moderate plaque 
psoriasis.•Proportion of participants 
who achieved a Psoriasis Symptoms Inventory (PSI)score of 0 (not at all) or 1 (mild) on every item at 
study visit time points 
specified in the SoA.•Estimand E2: This estimand is 
intended to provide a population level estimate of the treatment effect of the IP alone on a binary responder endpoint; without the 
benefit of additional prohibited 
medications, regardless of participants compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 vers us vehicle 
on measures of disease and symptom severity in participants with mild to •Change from baseline in 
PASI scores at study visit 
time points specified in the SoA (except Week 6). 
•Percent change from baseline •All other continuous secondary 
endpoints will be analyzed 
descriptively and using estimand E2 described above when appropriate.
[COMPANY_003]
PF-[ADDRESS_21765] 2020 
PFIZER CONFIDENTIAL
Page 14PSORIASIS
Objectives Endpoints Estimands
moderate plaque psoriasis. in PASI scores at study visit 
time points specified in the SoA.
•Proportion of participants 
with PGA score clear (0) or almost clear (1) and ≥2 points 
improvement from baseline 
at time points specified in the SoA.
•Percent change from baseline 
in BSA at study visit time points specified in the SoA.•All other categorical secondary 
endpoints will be analyzed descriptively and using estimand E1 described above when appropriate.
•To assess safety and 
tolerability of PF-07038124 
in participants with mild to moderate plaque psoriasis.•Incidence of treatment
emergent adverse events (AEs) and serious adverse events (SAEs), clinically significant changes in vital 
signs, electrocardiogram 
(ECG), and laboratory tests.
•Incidence of severity grades 
in skin tolerability at times indicated in SoA.•There is no defined estimand for 
these endpoints and they will be analyzed using [COMPANY_007] data standards as applicable.
Overall Design
This is a Phase 2a, randomized, double-blind, vehicle-controlled, parallel group, multicenter
study in the adult participants with mild to moderate AD or mild to moderate plaque psoriasis. The study will assess the efficacy, safety, tolerability, and PK of PF-07038124ointment. 
Number of ParticipantsA total of approximately 88 participants with AD or psoriasis will be randomly assigned to 
study intervention in this basket trial.
For AD, a maximum of approximately 56 participants will be randomly assigned to study 
intervention such that approximately 42 evaluable participants complete the study. Assuming a 25% drop out rate, approximately 28 participants will be randomized to either PF-07038124 or vehicle control to achieve approximately 21 completers in each group.Randomization will be stratified by [CONTACT_22789] (mild [Investigator's Global Assessment or IGA = 2] vs. moderate [IGA = 3]). Up to 25% of AD participants will have an IGA score of [ADDRESS_21766] 2020 
PFIZER CONFIDENTIAL
Page 15For psoriasis, a maximum of approximately 32 participants will be randomly assigned to 
study intervention such that approximately 24 evaluable participants complete the study.  Assuming a 25% drop out rate, approximately 16 participants will be randomized to PF-07038124 or vehicle control to achieve 12 completers in each group. Randomization willbe stratified by [CONTACT_22789] (mild [Physician Global Assessment or PGA = 2]vs. moderate [PGA = 3]). Up to 25% of psoriasis participants will have a PGA score of [ADDRESS_21767] study visit. 
Study intervention arms are shown in the following table.  
Table 1. Study Intervention Groups
Study Intervention 
Group (Indication)Target Number 
of Participants 
RandomizedApprox. Number 
of CompletersStudy Intervention
A (atopic dermatitis) 28 21 PF-07038124 ointment at 0.01% with QD 
dosing for 6 weeks
B (atopic dermatitis) 28 21 Vehicle ointment with QD dosing for 
6w e e k s
C (plaque psoriasis) 16 12 PF-07038124 ointment at 0.01% with QD 
dosing for 6 weeks
D (plaque psoriasis) 16 12 Vehicle ointment with QD dosing for 
6w e e k s
The study intervention for AD and psoriasis participants are the same.
A study design schematic is presented in Section 1.2 .
Data Monitoring Committee or Other Independent Oversight Committee: No
Statistical MethodsStatistical Methods for ADThe primary estimand will be estimated population-based average treatment effect on percent 
change from baseline in Eczema and Severity Index (EASI) score relative to vehicle at [ADDRESS_21768] on
the rates of Investigator’s Global Assessment (IGA) response (percentage of participantswith a score of 0 or 1 and a 2 point or greater decrease from baseline) at Week [ADDRESS_21769] (IP) in the absence of prohibited medication.
All other secondary continuous clinical endpoints will be analyzed using the primary
estimand, while all other secondary categorical clinical endpoints will be analyzed using thesecondary estimand described above. Other estimands may be used for some of the primary and secondary endpoints to examine the robustness of the results and to compare to available literature as needed. Details of these analyses will be presented in the Statistical Analysis Plan (SAP).
Statistical Methods for PsoriasisThe primary estimand will be the population average treatment effect on change from
baseline in Psoriasis Area and Severity Index (PASI) scores at Week [ADDRESS_21770] on the Physician 
Global Assessment (PGA) response rate: percentage of participants with a score of clear (0) or almost clear (1) and a [ADDRESS_21771] 2020 
PFIZER CONFIDENTIAL
Page 181.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evalua tions or 
assessments required to protect the well-being of the participant.
1.3.1. Atopic Dermatitis
ATOPIC DERMATITIS
Visit Identifiera Screening & 
WashoutDay 1
(Baseline)Week 1 Week 2 Week 4Week 6
(EOT)Follow-up
(EOS)Early 
Termination (ET)
Visit Window Day-42 to -1 N/ADay 8
±2Day 15
±2Day 29
±2Day 43
±228–[ADDRESS_21772] DoseN/A
Visit Number 1 2 3 4 5 6 7 N/A
Enrollment Procedures
Informed Consent X
Register Subject Using IRT System X
Medical History X X
Concomitant/Prior Treatments X X X X X X X X
Demography X
Eligibility Assessment X X
Randomization X
Clinical Assessments
Complete Physical ExaminationbXX X
Targeted Physical ExaminationbXX X X X
Weight X X
Height X
Vital SignscXX X X X X
ECGdXX X
C-SSRSeX
Laboratory Assessments
Serum FSH (WONCBP only) or Serum 
Pregnancy Test (WOCBP only)f X
[COMPANY_003]
PF-[ADDRESS_21773] 2020 
PFIZER CONFIDENTIAL
Page 19ATOPIC DERMATITIS
Visit Identifiera Screening & 
WashoutDay 1
(Baseline)Week 1 Week 2 Week 4Week 6
(EOT)Follow-up
(EOS)Early 
Termination (ET)
Visit Window Day-42 to -1 N/ADay 8
±2Day 15
±2Day 29
±2Day 43
±228–[ADDRESS_21774] DoseN/A
Visit Number 1 2 3 4 5 6 7 N/A
Urine Pregnancy Test (conducted at 
study site)g XXX X XXX
Hematology, Chemistry and UrinalysishX XXX X XX X
Fibrinogen, hsCRPhX XXX X XX X
IP Related Processes
Dispense dosing diary/PROs and 
instruct on usageX
Assess BSA & calculate IP need X X X X X
Body Map X X X X X
Weigh and dispense IP X X X X
IP application and observation (at site/at 
home in case of Home Health Visits)X X X X X
Record dose and time of IP application 
in dosing diary X →→ → X
Collect and weigh returned IP tubes for 
compliance checkXX  X  X X
Review of dosing diary/PROs X X X X X X X
Collect dosing diary/PROs XkXX
AD-Related Clinical Assessments
E A S I XX X X  X X XX
IGA X X X X X X X X
[COMPANY_003]CCI
PF-[ADDRESS_21775] 2020 
PFIZER CONFIDENTIAL
Page 20ATOPIC DERMATITIS
Visit Identifiera Screening & 
WashoutDay 1
(Baseline)Week 1 Week 2 Week 4Week 6
(EOT)Follow-up
(EOS)Early 
Termination (ET)
Visit Window Day-42 to -1 N/ADay 8
±2Day 15
±2Day 29
±2Day 43
±228–[ADDRESS_21776] DoseN/A
Visit Number 1 2 3 4 5 6 7 N/A
B S A X XXX X XX X
Safety Monitoring
Contraception check X X X X X X X X
Local Tolera bility AssessmentslXXX X XX X
Serious and non-serious AE monitoring X →→→ →→ XX
Patient Reported Outcomes (PRO) 
In-clinic completion
At-home completion
PP-NRSmX →→ XX X X X
Abbreviations: →= ongoing/continuous event; AD = Atopic Dermatitis; BSA = Body Surface Area;  C-SSRS = Columbia Suicide 
Severity Rating Scale; EASI = Eczema Assessment Severity Index; ECG = electrocardiogram; EOS = End of Study; EOT = End of 
Treatment; ET = Early termination; FSH = Follicle Stimulating Horm one; hsCRP= High-sensitivity C-reactive protein (hsCRP); IGA = I nvestigator’s Global Assessment; 
 IP = Investigational Product; PD = Pharmacodynamics;  
; PP-NRS = Peak Pruritis Numerical Rating Scale; PRO = Patient Reported 
Outcomes; .
a. Day relative to start of study treatment (Day 1). Except for Sc reening Visit and Day 1 Visit, Alternative Measures ( Section 10.9 ) may be implemented in case of public 
emergencies. Please refer to Section 10.9 for the details about the assessments that may be performed during a Telehealth Visit (including Efficacy Assessments) or a Home 
Health Visit.
b. Physical Examination: Physical assessments may be performed in the event of Home Health Visit.c. Vital Signs: Temperature (Oral or tympanic temperature), pulse rate, and blood pressure will be taken in supi[INVESTIGATOR_2547], aft er the participant has been lying calmly for a 
minimum of 5 minutes.  Assessment of vital signs should precede blood draw for clinical laboratory tests.
d. Local read, single ECG (in supi[INVESTIGATOR_2547]) at all time points indicat ed.  To ensure safety of the participant, a qualified i ndividual (eg, sub-investigator) at the investigator site 
will make comparisons to baseline measurements taken at Day 1. Triplicate ECG will be conducted as appropriate per Section 8.2.4 .
e. Site staff is to administer the Columbia Suicide Severity Rating Scale (C-SSRS) to all participants at screening and score im mediately.  Participants who have recent or active 
suicidal ideation or behavior or clinically significant depression will be excluded from the study per Section 5.[ADDRESS_21777] 2020 
PFIZER CONFIDENTIAL
Page 21f. Serum FSH (WONCBP only) or Serum Pregnancy test (WOCBP only): For Women of Non-Childbearing Potential (WONCBP), serum follicle stimulating hormone (FSH) 
test to be performed at Screening to confirm postmenopausal status in female subjects who have been amenorrheic for at least [ADDRESS_21778] 
is required for all Women of Childbearing Potential (WOCBP).
g. Urine Pregnancy Tests must be performed prior to dosing with the investigational product for female subjects of childbearing p otential. Two negative pregnancy tests are 
required before receiving investigational product ([ADDRESS_21779] administration). 
h. Blood draw for Protocol-Required Safety Laboratory Assessments ( Appendix 2 ) on Day 1 will be performed before the in-clinic IP application.  Laboratory tests with 
abnormal results may be repeated once during the screening period; the last value will be used to determine eligibility. 
k. Only for participants who do not meet eligibility criteria.
l. Local tolerability at the site of IP application will be assessed pre-dose and immediately after post-dose.
m. PP-NRS: At the screening visit or at least 7 days prior to Day 1, site staff will dispense the ePRO device (or paper PROs) and re view instructions for completion.
[COMPANY_003]C
C
I
PF-[ADDRESS_21780] 2020 
PFIZER CONFIDENTIAL
Page 221.3.2. Psoriasis
PSORIASIS
Visit Identifiera Screening & 
WashoutDay 1
(Baseline)Week 1 Week 2 Week 4Week 6
(EOT)Follow-up
(EOS)Early Termination 
(ET)
Visit Window Day -42 to -1 N/A Day 8±2 Day 15±2 Day 29±2 Day 43±228–[ADDRESS_21781] DoseN/A
Visit Number 1 2 3 4 5 6 7 N/A
Informed Consent X
Register Subject Using IRT System X
Medical History X X
Concomitant/Prior Treatments X X X X X X X X
Demography X
Eligibility Assessment X X
Rando mization X
Clinical assessments 
Complete Physical ExaminationbXX X
Targeted Physical ExaminationbXXX X X
Weight X X
Height X
Vital SignscXX X X X X
ECGdXX X
C-SSRSeX
Laboratory assessments
Serum FSH (WONCBP only) or Serum 
Pregnancy Test (WOCBP only)fX
Urine Pregnancy Test (conducted at 
study site)gXX X XX X X
Hematology, Chemistry and UrinalysishXX X X X X X X
Fibrinogen, hsCRPhXX X X X X X X
[COMPANY_003]CCI
PF-[ADDRESS_21782] 2020 
PFIZER CONFIDENTIAL
Page 23PSORIASIS
Visit Identifiera Screening & 
WashoutDay 1
(Baseline)Week 1 Week 2 Week 4Week 6
(EOT)Follow-up
(EOS)Early Termination 
(ET)
Visit Window Day -42 to -1 N/A Day 8±2 Day 15±2 Day 29±2 Day 43±228–[ADDRESS_21783] DoseN/A
IP Related Processes
Dispense dosing diary/PROs and 
instruct on usageX
BSA & calculate IP need X X X X X
Body Map X X X X X
Weigh and dispense IP X X X X
IP application and observation (at site/at 
home in case of Home Health Visits)X X X X X
Record dose and time of IP application 
in dosing diary X →→→ X
Collect and weigh returned IP tubes for 
compliance checkXX  X  X X
Review of dosing Diary/PROs X X X X X X X
Collect dosing Diary/PROs XkXX
Psoriasis-Related Clinical assessments
PASI X X X X X X X X
PGA X X X X X X X X
BSA X X X X X X X X
Safety Monitoring
Contraception check X X X X X X X X
Local Tolerability AssessmentslXX X XX X X
Serious and non-serious AE monitoring X →→ → →→ → X
Patient Reported Outcomes (PRO) 
In-clinic completion
At-home completion
PSImX → → X X X X X
[COMPANY_003]CCI
CCI
PF-[ADDRESS_21784] 2020 
PFIZER CONFIDENTIAL
Page 24Abbreviations: →= ongoing/continuous event; BSA = Body Surface Area; C-SSRS = Columbia Suicide Severity Rating Scale; 
ECG = electrocardiogram; EOS = End of Study; EOT = End of Treatment; ET = Early Termination; FSH = Follicle Stimulating Hormone; hs CRP= High-sensitivity C-reactive 
protein (hsCRP); ; IP = Investigational Product; PASI = Psoriasis Area and Severity index; PGA = Physicians Global Assessment;  
; PRO = Patient Reported Outcomes; PSI=Psoriasis Symptom Inventory.
a. Day relative to start of study treatment (Day 1). Except for Screening Visit and Day 1 Visit, alternative measures ( Section 10.9 ) may be implemented in case of public 
emergencies. Please refer to Section 10.9 for the details about the assessments that may be performed during a Telehealth Visit (including Efficacy Assessments) or a Hom e 
Health Visit.
b. Physical Examination: Physical assessments may be performed in the event of Home Health Visit.
c. Vital Signs: Temperature (Oral or tympanic temperature), pulse rate, and blood pressure will be taken in supi[INVESTIGATOR_2547], aft er the participant has been lying calmly for a 
minimum of 5 minutes.  Assessment of vital signs should precede blood draw for clinical laboratory tests.
d. Local read, single ECG (in supi[INVESTIGATOR_2547]) at all time points indicated. To ensure safety of the participant, a qualified ind ividual (eg, sub-investigator) at the investigator site 
will make comparisons to baseline measurements taken at Day 1. Triplicate ECG will be conducted as appropriate per Section 8.2.4 .
e. Site staff is to administer the Columbia Suicide Severity Scale (C-SSRS) to all participants at screening and score immediate ly.  Participants who have recent or active 
suicidal ideation or behavior or clinically significant depression will be excluded from the study.
f. Serum FSH (WONCBP only) or Serum Pregnancy test: For Women of Non-Childbearing Potential (WONCBP), serum follicle stimulating hormone (FSH) test to be 
performed at Screening to confirm postmenopausal status in female subjects who have been amenorrheic for at least [ADDRESS_21785] is required 
for all Women of Childbearing Potential (WOCBP).
g. Urine Pregnancy Tests must be performed prior to dosing with the investigational product for female subjects of childbearing potential. Two negative pregnancy tests are 
required before receiving investigational product ([ADDRESS_21786] administration).
h. Blood draw for Protocol-Required Safety Laboratory Assessments ( Appendix 2 ) on Day 1 will be performed before the in-clinic IP application.  Laboratory tests with 
abnormal results may be repeated once during the screening period; the last value will be used to determine eligibility. 
k. Only for participants who do not meet eligibility criteria.
l. Local tolerability at the site of IP application will be assessed pre-dose and immediately after post-dose.
m. PSI: At the screening visit or at least 7 days prior to Day 1, s ite staff will dispense the ePRO device (or paper PROs) and revi ew instructions for completion.
[COMPANY_003]CCI
CCI
CCICCI
C
C
I
PF-[ADDRESS_21787] 2020 
PFIZER CONFIDENTIAL
Page 262. INTRODUCTION
PF-07038124 is a topi[INVESTIGATOR_22724] 4 (PDE4) inhibitor that is being investigated for 
the treatment of atopic dermatitis (AD) and plaque psoriasis (psoriasis).
2.1. Study Rationale 
The purpose of the study is to investigate the efficacy, safety, tolerability and 
pharmacokinetics of topi[INVESTIGATOR_22725]-07038124 in participants with mild to moderate AD or mild to moderate psoriasis.  Participants will receive either PF-07038124 or a vehicle control for 6 weeks.
2.2. Background 
2.2.1. Role of Proinflammatory Cytokines in AD and PsoriasisATOPIC DERMATITIS: Atopic dermatitis (AD), also known as atopic eczema, is a
common, chronic, inflammatory skin disorder char acterized by [CONTACT_22790], intense 
pruritus, and a general deterioration in quality of life.  AD can affect any age group.  Prevalence estimates suggest approximately 10% of adults and 10%-20% of children suffer from AD, and up to 18% of those affected with AD suffer with severe disease.  
There are a limited number of treatments available for AD.  Current treatments for AD 
include emollients, topi[INVESTIGATOR_11930] (eg, betamethasone, clobetasol, fluocinonide), topi[INVESTIGATOR_22726] (eg, pi[INVESTIGATOR_031], tacrolimus), and coal tar preparations.  Crisaborole ointment, 2% (weight by [CONTACT_8497]) (20 mg/g), a PDE4 inhibitor, is approved in the [LOCATION_002] (US; Eucrisa
®) as a topi[INVESTIGATOR_22727] 3 months of age and 
older with mild to moderate AD; and in Canada (Eucrisa®), Israel, the European Union (EU), 
Australia and China (Staquis®) as a topi[INVESTIGATOR_22727] 2 years of age and 
older with mild to moderate AD. Additional treatments generally reserved for severe AD include phototherapy (eg, ultraviolet A [UVA] light with or without psoralen) and systemic 
agents (eg, corticosteroids, cyclosporine, recombinant IFN- γ, mycophenolate mofetil, 
methotrexate).  None of the currently available therapi[INVESTIGATOR_22728] a cure; therefore, the main aims of existing treatments are to reduce the occurrence of acute flares, increase the time between relapses, reduce pruritus and reduce the resulting sleep disturbances.
For most AD patients not responding to topi[INVESTIGATOR_22729], off-label use of 
systemic agents, which includes both oral corticosteroids and oral immunosuppressants remain the last viable treatment option.  Dupi[INVESTIGATOR_22730], an interleukin (IL)-[ADDRESS_21788] 2020 
PFIZER CONFIDENTIAL
Page 27The T-helper-2 response contribute to AD-associated skin inflammation and itch.1The 
pathogenic role that the T-helper 2 cells (Th2) deri ved cytokines, IL-4 and IL-13, play in AD 
has been demonstrated through the clinical efficacy of dupi[INVESTIGATOR_12458], an antibody to the IL-4 receptor that blocks the activity of both IL-4 and IL-13.
2
PSORIASIS: The most common variant of psoriasis, plaque psoriasis (psoriasis vulgaris), is a chronic inflammatory skin disease characterized by [INVESTIGATOR_5697], scaly, raised plaques.  Chronic plaque psoriasis is a common skin disorder with a worldwide prevalence of 2%. Although psoriasis primarily affects the skin and is not a life-threatening disease, it can profoundly impact the patient’s quality of life (QoL) resulting in an impairment akin to other major diseases, such as type 2 diabetes, myocardial infarction, and arthritis. Current treatments for psoriasis include topi[INVESTIGATOR_8593], phototherapy, systemic non-biological therapi[INVESTIGATOR_014] (methotrexate,cyclosporin, acitretin, apremilast [Otezla
®]) and biologics.
Proinflammatory cytokines such as tumor necrosis factor (TNF) α, interferon (IFN) γand 
IL-23/T-helper-[ADDRESS_21789] been shown to be effective for the treatment of psoriasis in clinical trials.4
Biologic agents used in the treatment of psoriasis include multiple anti-TNF agents (such as infliximab, adalimumab, etanercept), anti-IL-12/IL-[ADDRESS_21790] (Otezla
®) may reduce production of pro ‐inflammatory
TNF-αand IFN-γby [CONTACT_22791] (cAMP) levels.
2.2.2. Description of Investigational Product: Mechanism of Action
Phosphodiesterases (PDE) are a family of enzymes that breakdown the ubiquitous second 
messengers, cAMP and cyclic guanosine monophosphate (cGMP), that regulate various cellular processes.  PDE4 is a subfamily that includes the four isozymes, each encoded by [CONTACT_22792], PDE4 A, B, C and D.  Inhibitors of the PDE4 family have been the focus of intense drug development over many years due to their broad potential in inflammatory diseases such as AD and psoriasis.  For example, apremilast (Otezla
®) is an oral 
small-molecule inhibitor of PDE4 that is approved for the treatment of patients with moderate to severe plaque psoriasis and active psoriatic arthritis. Crisaborole (Eucrisa
®,
Staquis®) is a topi[INVESTIGATOR_22731]4 inhibitor that has demonstrated efficacy in clinical 
trials5and is approved for the treatment of mild to moderate AD as described previously. In 
addition, other topi[INVESTIGATOR_22732]4 inhibitors, such as roflumilast (ARQ-151), have shown activity in the treatment of psoriasis.
[ADDRESS_21791] 2020 
PFIZER CONFIDENTIAL
Page 28PF-07038124 is a potent and selective PDE4 inhibitor intended to be used for topi[INVESTIGATOR_22733].   
 
PF-07038124 inhibits cytokine production and release from T cells and monocytes in peripheral blood mononuclear cells (PBMC) over a range of concentrations that is dependent on the cytokine that is being modulated. 
 
 
 
 PF-[ADDRESS_21792] the activity of other topi[INVESTIGATOR_22734], including topi[INVESTIGATOR_11930], Janus kinase (JAK) inhibitors and the PDE4 inhibitor crisaborole (Eucrisa
®).  
 
 
 
 
 
2.2.3. Preclinical Safety Data 
In the pi[INVESTIGATOR_22735] 3-month toxicity studies in rats (oral) and minipi[INVESTIGATOR_14107] (dermal), the systemic 
no-observed-adverse-effect levels (NOAEL) were identified as 4 mg/kg/day and 0.0104 mg/cm
2/day (0.0052 mg/cm2, BID), respectively, with systemic exposures of 2x and 
1.2x, respectively, the projected maximum human exposure (uC av= 9 pg/mL). The systemic 
NOAEL exposure identified in the more sensitive nonclinical species (minipig) was 11 pg/mL (C
av, unbound).  The local (dermal) NOAEL was identified at the 
0.03% concentration (BID) corresponding to 0.0052 mg/cm2/day (0.0026 mg/cm2, BID) and 
represents an 17x multiple to the projected maximum human dermal dose of 
0.0003 mg/cm2/day in the current study. Based on the completed nonclinical studies, local 
(skin) and systemic (cardiovascular, nervous, and gastrointestinal) target organs/systems were identified.  Local reactions (erythema, edema) were observed in minipi[INVESTIGATOR_22736]≥0.[ZIP_CODE] mg/cm
2/day (5.8x the highest planned clinical dermal dose, 0.0003 mg/cm2/day).  
A potential for skin sensitization by [INVESTIGATOR_16335]-[ADDRESS_21793] Level (NOEL) of 0.015 mg/cm
2/day (50x the highest 
planned clinical dermal dose, 0.0003 mg/cm2/day).  Cardiovascular effects included increases 
in heart rate, contractility, and/or blood pressure in rats and/or dogs, and vascular 
[COMPANY_003]CCI
CCI
CCI
CCI
PF-[ADDRESS_21794] 2020 
PFIZER CONFIDENTIAL
Page 29injury/compromise (in mesentery, kidney, adrenal gland, and/or bladder) in rats and/or 
minipi[INVESTIGATOR_14107].  Clinical signs indicative of nervous system effects (eg, ataxia, decreased activity, hunched posture, twitching, and/or tremors) and gastrointestinal effects (emesis, salivation, and/or soft/liquid feces) were also observed in rats, dogs, and/or minipi[INVESTIGATOR_14107], mostly at non-tolerated doses.  These systemic effects in nonclinical species are consistent with those reported for oral selective PDE4 inhibitors.  PF-07038124 was negative for mutagenicity, positive in an in vitro micronucleus assay at high concentrations via aneugenic mechanism, but negative in an in vivo rat micronucleus assessment.  PF-07038124 was not phototoxic and no further photosafety testing is recommended.  Rat and rabbit embryo-fetal development (EFD) was assessed after oral administration of PF-07038124 to pregnant animals.  PF-07038124 did not cause any effects on embryo-fetal development following oral administration at doses up to 4 mg/kg/day (rats) and 8 mg/kg/day (rabbits), respectively.  The developmental NOAEL exposures in pregnant rats and rabbits corresponded to 1.7x and 2.7x the maximum planned clinical exposure on an unbound C
av(uC av) basis. In addition, no 
effects on fertility were observed in female rats after oral administration of PF-07038124 up to 4 mg/kg/day (4.1x the maximum planned dose on an uC
avcomparison basis).
The nonclinical safety profile of PF-[ADDRESS_21795] 2020 
PFIZER CONFIDENTIAL
Page 312.3. Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-07038124 may be found in the investigator’s brochure (IB), which is the SRSD for this study.
[COMPANY_003]CCI
PF-[ADDRESS_21796] 2020 
PFIZER CONFIDENTIAL
Page 322.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention PF-07038124
Adverse Nonclinical findings – PDE4 inhibitor 
associated vasculitisVasculitis is an effect associated with 
administration of oral PDE4 inhibitors in 
nonclinical species, correlates with an acute 
phase reaction, and occurs at doses above the NOAEL and also systemic exposures at the clinical Maximum Recommended Human Dose (MRHD) for oral PDE4 inhibitors.Participants will be assessed for safety at regular 
intervals throughout the study (including monitoring 
of acute-phase reactants such as fibrinogen and 
C-reactive protein), systemic exposure will also be assessed.
Adverse Nonclinical findings – PDE4-related nervous system and gastrointestinal effect (a class effect of AEs observed with PDE4 inhibitors)Clinical signs indicative of nervous system 
effects (eg, ataxia, decreased activity, hunched 
posture, twitching, and/or tremors) and 
gastrointestinal effects (emesis, salivation, and/or soft/liquid feces) were observed in rats, dogs, and/or minipi[INVESTIGATOR_14107], at non-tolerated doses.Participants will be assessed for safety at regular 
intervals throughout the study.
Adverse Nonclinical findings – Potential Skin SensitizationThe potential for skin sensitization was identified 
as a risk in nonclinical species at dermal concentrations 50x above the planned dose 
concentration of 0.01%, with a no observed 
effect level of 0.06% ointment.Participants will be assessed for safety at regular 
intervals throughout the study, including assessment of the administration site. Participants with any 
history of angioedema or anaphylaxis to topi[INVESTIGATOR_22737].
Use of a placebo arm Participants on placebo may experience a 
worsening of disease.Participants will be assessed for safety at regular 
intervals throughout the study.  AD and psoriasis arenot life-threatening diseases.
[COMPANY_003]
PF-[ADDRESS_21797] 2020 
PFIZER CONFIDENTIAL
Page 332.3.2. Benefit Assessment
Based on its cytokine inhibition profile, topi[INVESTIGATOR_22738]-07038124 is anticipated 
to provide potential therapeutic benefit in the treatment of AD by [CONTACT_22793] T-helper-2 response and in the treatment of psoriasis by [CONTACT_22794]- α. Other 
PDE4 inhibitors, such as crisaborole (Eucrisa®, Staquis®), apremilast (Otezla®), and
roflumilast (ARQ-151)6have demonstrated efficacy in the treatment of AD or psoriasis.
Based on the clinical data for these PDE4 inhibitors, participants in this study may receive a beneficial effect, in addition to regular intensive clinical trial assessment to support participants’ management of AD or psoriasis.
The included vehicle has important emollient properties. Some vehicle excipi[INVESTIGATOR_22739] a 
more pronounced beneficial effect on the skin and can improve clinical appearance and skin barrier function. In particular, white petrolatum, the primary excipi[INVESTIGATOR_22740]-07038124 ointment, 0.01%, was selected for its emollient properties and favorable tolerability profile. The use of topi[INVESTIGATOR_22741].
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures to minimize risk to participants in this study, the potential 
risks identified in association with PF-07038124 are justified by [CONTACT_22795].
The Benefit/Risk balance of PF-07038124 in Study C3941002 is considered favorable and 
supported by:
•The satisfactory safety and local tolerability profile on PF-07038124 to date based on 
non-clinical studies 
•The expected efficacy of PF-07038124 for the treatment of AD and psoriasis based 
on pre-clinical data generated with PF-07038124 as well as the efficacy of other approved topi[INVESTIGATOR_22732]4 inhibitors for the treatment of mild to moderate AD (Eucrisa
®/Staquis®) and oral PDE4 inhibitors for the treatment of moderate to severe 
psoriasis (Otezla®).
Participants will be monitored closely during the study for safety and local tolerability 
adverse events by [CONTACT_22796].
In conclusion, [COMPANY_007] considers that the clinical experience to date with PF-07038124 support 
the continued development of PF-07038124 for the treatment of AD and psoriasis supportingthe initiation of Phase 2a study C3941002. Additional background information on PF-07038124 can be found in the current version of the IB, especially the Summary of Data and Guidance for the Investigator (Section 7 of the IB).
[COMPANY_003]CCI
PF-[ADDRESS_21798] 2020 
PFIZER CONFIDENTIAL
Page 343. OBJECTIVES, ESTIMANDS, AND ENDPOINTS
3.1. Atopic Dermatitis
ATOPIC DERMATITIS
Objectives Endpoints Estimands
Primary Objective Primary Endpoint Primary Estimands 
•To compare the efficacy of 
PF-07038124 versus vehicle on percent change from baseline in Eczema Area and Severity Index 
(EASI) in participants with 
mild or moderate atopic dermatitis (AD).•Percent change from baseline in 
EASI total score at Week 6.•Estimand E1: This estimand 
is intended to provide a population level estimate of the treatment effect of theinvestigational product (IP)
on a continuous endpoint; 
without the benefit of additional prohibited medications during treatment and regardless of 
participant compliance with 
the IP dosing.
Secondary Objectives: Secondary Endpoints Secondary Estimands 
•To compare the efficacy of 
PF-07038124 versus vehicle, 
using Investigator’s Global 
Assessment (IGA) score assessment as endpoint in participants with mild or moderate AD.•Proportion of participants 
achieving IGA score of clear (0) 
or almost clear (1) (on a 5-point 
scale) and a reduction from baseline of ≥2 points at Week 6.•Estimand E2: This estimand 
is intended to provide a 
population level estimate of 
the treatment effect of the IP on a binary responder endpoint; without the benefit of additional prohibited medications and regardless of 
a participant compliance with 
the IP dosing.
•To compare the efficacy of 
PF-07038124 versus vehicle, using measures of disease 
severity and symptoms as 
endpoints in participants with mild or moderate AD.•Proportion of participants 
achieving EASI 75 (75% improvement from 
baseline) at study visit time 
points specified in the SoA.•Estimand E2: This estimand 
is intended to provide a population level estimate of 
the treatment effect of the IP 
on a binary responder endpoint; without the benefit of additional prohibited medications and regardless of a participant compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 versus vehicle, using measures of patient reported outcomes (PRO), in 
participants with mild or •Proportion of participants having 
≥4 points of reduction in weekly 
averages of Peak Pruritus Numerical Rating Scale 
(PP-NRS) from baseline at study
visit time points specified in the •Estimand E2: This estimand 
is intended to provide a population level estimate of the treatment effect of the IP 
on a binary responder 
endpoint; without the benefit 
[COMPANY_003]
PF-[ADDRESS_21799] 2020 
PFIZER CONFIDENTIAL
Page 35ATOPIC DERMATITIS
Objectives Endpoints Estimands
moderate AD. SoA. of additional prohibited 
medications and regardless of 
a participant compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 versus vehicle, 
on measures of disease and 
symptom severity inparticipants with mild or moderate AD.•Change from baseline in EASI 
total score at study visit time points specified in the SoA.
•Proportion of participants 
achieving IGA score of clear (0) or almost clear (1) at study visit time points specified in the SoA.
•Percent change from baseline in 
affected Body Surface Area (BSA) at study visit time points specified in the SoA.•All continuous secondary 
endpoints will be analyzed 
descriptively and using 
estimand E1 described above, when appropriate.
•All categorical secondary 
endpoints will be analyzed 
descriptively and using 
estimand E2 described above, when appropriate.
•To characterize the safety 
and tolerability of 
PF-07038124 vers us vehicle 
in participants with mild or moderate AD.  •Incidence of treatment emergent 
adverse events (AEs) and serious 
adverse events (SAEs), clinically significant changes in vital signs, electrocardiogram (ECG), and laboratory tests.
•Incidence of severity grades in 
skin tolerability at times indicated 
in SoA.•There is no defined estimand 
for these endpoints and they 
will be analyzed using [COMPANY_007] data standards as applicable.
[COMPANY_003]CCI
PF-[ADDRESS_21800] 2020 
PFIZER CONFIDENTIAL
Page 363.2. Psoriasis
PSORIASIS
Objectives Endpoints Estimands
Primary: Primary: Primary:
•To compare the efficacy of 
PF-07038124 versus vehicle 
on change from baseline in 
Psoriasis Area and Severity Index (PASI) score in participants with mild to moderate plaque psoriasis. • Change from baseline in PASI 
score at Week 6.•Estimand E1: This estimand is 
intended to provide a 
population level estimate of 
the treatment effect of the investigational product (IP) alone on a continuous endpoint; without the benefit of additional prohibited 
medications, regardless of 
participants compliance with the IP dosing.
Secondary: Secondary: Secondary:
•To compare the efficacy of 
PF-07038124 versus  vehicle
on Physician GlobalAssessment (PGA) score in participants with mild to moderate plaque psoriasis.•Proportion of participants with 
PGA score clear (0) or almost 
clear (1) (on a 5-point scale)and ≥2 points improvement 
from baseline at Week 6. •Estimand E2: This estimand 
is intended to provide a 
population level estimate of the treatment effect of the IP alone on a binary responder endpoint; without the benefit 
of additional prohibited 
medications, regardless of 
[COMPANY_003]CCI
PF-[ADDRESS_21801] 2020 
PFIZER CONFIDENTIAL
Page 37PSORIASIS
Objectives Endpoints Estimands
participants compliance with 
the IP dosing.
•To compare the efficacy of 
PF-07038124 vers us vehicle 
on the proportion of 
participants with mild to moderate plaque psoriasis achieving PASI 75. •Proportion of participants 
achieving PASI 75 (75% or 
greater improvement from 
baseline) at study visit time points specified in the SoA.•Estimand E2: This estimand 
is intended to provide a 
population level estimate of 
the treatment effect of the IP alone on a binary responder endpoint; without the benefit of additional prohibited medications, regardless of 
participants compliance with 
the IP dosing.
•To compare the efficacy of 
PF-07038124 versus vehicle, using measures of 
patient reported outcomes 
(PRO), in participants with mild or moderate plaque psoriasis.•Proportion of participants who
achieved a Psoriasis Symptoms Inventory (PSI) score of 0 (not 
at all) or 1 (mild) on every item 
at study visit time points specified in the SoA.•Estimand E2: This estimand is 
intended to provide a population level es timate of 
the treatment effect of the IP 
alone on a binary responder endpoint; without the benefit of additional prohibited medications, regardless of participants compliance with the IP dosing.
•To compare the efficacy of 
PF-07038124 versus  vehicle 
on measures of disease and symptom severity in 
participants with mild to 
moderate plaque psoriasis. •Change from baseline in PASI 
scores at study visit time points specified in the SoA (except 
Week 6). 
•Percent change from baseline in 
PASI scores at study visit time points specified in the SoA. 
•Proportion of participants with 
PGA score clear (0) or almost clear (1) and ≥2 points 
improvement from baseline at 
time points specified in theSoA.
•Percent change from baseline in 
BSA at study visit time points specified in the SoA.•All other continuous 
secondary endpoints will beanalyzed descriptively and using estimand E1 described above when appropriate.
•All other categorical 
secondary endpoints will be analyzed descriptively and using estimand E2 described above when appropriate.
•To assess safety and 
tolerability of PF-07038124
in participants with mild to moderate plaque psoriasis.•Incidence of treatment emergent 
adverse events (AEs) and serious adverse events (SAEs), clinically significant changes in 
vital signs, electrocardiogram 
(ECG), and laboratory tests.
•Incidence of severity grades in •There is no defined estimand 
for these endpoints and they will be analyzed using [COMPANY_007] data standards as applicable.
[COMPANY_003]
PF-[ADDRESS_21802] 2020 
PFIZER CONFIDENTIAL
Page 394. STUDY DESIGN
4.1. Overall DesignThis is a phase 2a, randomized, double blind, vehicle controlled, parallel group, multicenter 
study on the efficacy, safety, tolerability and PK of PF-07038124 0.01% QD versus vehicle control in the treatment of adult participants with mild to moderate AD or mild to moderate plaque psoriasis.  In this study the efficacy of PF-07038124 ointment versus vehicle will be assessed in two different indications – there is a separate vehicle control group for each indication.
A total of approximately 88 participants with AD or psoriasis will be randomly assigned to 
study intervention in this basket trial design.
For AD, a maximum of approximately 56 participants will be randomly assigned to study 
intervention such that approximately 42 evaluable participants complete the study.Assuming a 25% drop out rate, approximately 28 participants will be randomized to either PF-07038124 or vehicle control to achieve approximately 21 completers in each group.Randomization will be stratified by [CONTACT_22789] (mild [Investigator's Global Assessment or IGA = 2] vs. moderate [IGA = 3]). Up to 25% of AD participants will have an IGA score of 2 at baseline. 
For psoriasis, a maximum of approximately 32 participants will be randomly assigned to 
study intervention such that approximately 24 evaluable participants complete the study.  Assuming a 25% drop out rate, approximately 16 participants will be randomized to PF-07038124 or vehicle control to achieve 12 completers in each group. Randomization willbe stratified by [CONTACT_22789] (mild [Physician Global Assessment or PGA = 2]vs. moderate [PGA = 3]). Up to 25% of participants will have a PGA score of [ADDRESS_21803] study visit. The study intervention arms and duration for AD and psoriasis participants are the same (See Section 1.1 for detailed Study Intervention Groups and Section 1.2 for Study 
Schema).
4.2. Scientific Rationale for Study Design
This 6-week study is the first time a topi[INVESTIGATOR_22725]-07038124 ointment is being evaluated in the
AD and psoriasis populations.  Previous [COMPANY_007] trials in these indications indicate that a 6-week duration is appropriate to assess the efficacy, safety and tolerability.  The current nonclinical toxicology package supports the study durations of up to 12 weeks.
For AD the primary endpoint is percent change from baseline in Eczema Area and Severity 
Index (EASI); secondary endpoints include Investigator’s Global Assessment (IGA).
[COMPANY_003]
PF-[ADDRESS_21804] 2020 
PFIZER CONFIDENTIAL
Page 40For psoriasis the primary endpoint is percent change from baseline in Psoriasis Area and 
Severity Index (PASI); the secondary endpoints include Physician Global Assessment (PGA).
Human reproductive safety data are limited for PF-07038124, but there is no suspi[INVESTIGATOR_22742].  In addition, EFD studies conducted in pregnant rats and rabbits at exposures that correspond to 1.7x and 2.7x the maximum planned clinical exposure did not cause any effects on embryo-fetal development.  See Appendix 4 for contraceptive requirements.
4.2.1. Participant Input into Design
Not applicable.
4.3. Justification for Dose
The nonclinical safety profile of PF-07038124 following systemic administration to rats and 
topi[INVESTIGATOR_22743] 3 months in duration(See Section 2.2 ). The dose proposed for this study was determined considering all relevant 
information obtained from nonclinical safety studies, incorporating the NOAEL from 3-month studies in minipi[INVESTIGATOR_14107], together with the systemic exposure observed following topi[INVESTIGATOR_22744]-07038124 to healthy participants. As a result, the dose strength of PF-07038124 selected for this study is 0.01%, applied once daily. 
[COMPANY_003]CCI
CCI
PF-[ADDRESS_21805] completed the study if he/she has completed all phases of 
the study, including the last visit shown in the SoA.
The end of the study is defined as the date of the last visit of the last participant in the study 
in the trial globally.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate.  All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
The inclusion criteria for AD and psoriasis are overlappi[INVESTIGATOR_22745]. Details of the 
overlappi[INVESTIGATOR_22746] 5.1.1 ; Disease-specific inclusion 
criteria are provided in Section [IP_ADDRESS] and Section [IP_ADDRESS] for AD and psoriasis respectively.
Participants are eligible to be included in the study only if all of the following criteria apply:5.1.1. General Inclusion Criteria Applicable for both AD and psoriasis
1. Male or female participants between the ages of 18 and 70 years, inclusive, at Visit 1
(Screening Visit/time of informed consent).
•Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.
2. Body weight ≥50 kg and Body Mass Index (BMI) ≥17.5 kg/m2up to 40 kg/m2
(inclusive).
3. Capable of giving signed informed consent as described in Appendix [ADDRESS_21806] 2020 
PFIZER CONFIDENTIAL
Page 435.1.2. Disease-Specific Inclusion Criteria 
[IP_ADDRESS]. AD Specific Inclusion Criteria
1. Have been diagnosed with AD for at least 3 months prior to Day 1; the clinical 
diagnosis of AD will be confirmed according to the criteria of Hanifin and Rajka7
(Appendix 11 ).
2. Have an Investigator’s Global Assessment (IGA) score of 2 (mild), or 3 (moderate) at 
both the Screening and Day 1/Randomization. Note: Refer to Section [IP_ADDRESS] for the
assessment of 5-point IGA.
3. Have AD covering 5% to 20% (inclusive) of BSA (excluding the scalp) at both the 
Screening and Day 1/Randomization.  Note: Refer to Section [IP_ADDRESS] for detailed 
methods of calculating treatable BSA.
4. Have an EASI total score of ≥3 to ≤21 at Screening and at Day 1/Randomization.
Note: Refer to Section [IP_ADDRESS] for method of calculating EASI scores.
5. Have a Baseline Peak Pruritis Numerical Rating Scale (PP-NRS) average score of 
≥2 assessed at Day 1/Randomization.
[IP_ADDRESS]. Psoriasis Specific Inclusion Criteria
1. Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 
6 months prior to Day 1.
2. Participants with a Physician Global Assessment (PGA) score of 2 (mild), or 
3 (moderate) at Screening and Day 1. Note: Refer to Section [IP_ADDRESS] for the 
assessment of 5-point PGA.
3. Having plaque psoriasis covering 5% to 15% (inclusive) of BSA (excluding the scalp)
at both the Screening and Day 1/Randomization.  Note: Refer to Section [IP_ADDRESS] for 
detailed methods of calculating treatable BSA.
5.2. Exclusion Criteria
The exclusion criteria for AD and psoriasis are the same.
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Presence of skin comorbidities that would interfere with study assessment or response 
to treatment.
[COMPANY_003]
PF-[ADDRESS_21807] 2020 
PFIZER CONFIDENTIAL
Page 442. Any psychiatric condition including recent or active suicidal ideation or behavior that 
meets any of the following criteria at Screening or Day 1: 
a. Suicidal ideation associated with actual intent and/or plan in the past year: “Yes” 
answers on items 4 “some intent to act without specific plan” or 5 “specific plan and intent” of the Columbia Suicide Severity Rating Scale (C-SSRS);
b. Previous history of suicidal behaviors in the past 5 years: “Yes” answer (for 
events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS;
c. Any lifetime history of serious or recurrent suicidal behavior;d. The presence of any current major psychiatric disorder that is not explicitly 
permitted in the inclusion/exclusion criteria;
e. In the opi[INVESTIGATOR_22747] (or designee) exclusion is required.
3. Current or recent history (within approximately 3 months prior to Day 1) of severe, 
progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.
4. A history of systemic (within approximately 3 months prior to Day 1), chronic or 
acute skin infection (within approximately 2 weeks prior to Day 1) requiring hospi[INVESTIGATOR_059], parenteral antimicrobial therapy, or as otherwise judged clinically significant by [CONTACT_093].
5. A known immunodeficiency disorder or a first degree relative with a hereditary 
immunodeficiency.
6. Undergone significant trauma or major surgery within [ADDRESS_21808] a history of angioedema or anaphylaxis to topi[INVESTIGATOR_22748].
9. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality that may increase the risk 
of study participation or, in the investigator’s judgment, make the participant 
inappropriate for the study.
[COMPANY_003]
PF-[ADDRESS_21809] 2020 
PFIZER CONFIDENTIAL
Page 45Prior/Concomitant Therapy:
10. Has received any of the prohibited medications/therapi[INVESTIGATOR_22749]/therapy (see Appendix 10 ).
Prior/Concurrent Clinical Study Experience:
11. Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_21810] dose of study interventionused in this study (whichever is longer). 
Note : Any investigational or experimental therapy taken or procedure performed for 
AD, psoriasis, psoriatic arthritis or rheumatoid arthritis in the previous 1 year should 
be discussed with the [COMPANY_007] Medical Monitor (or designee).  Participants cannotparticipate in studies of other investigational or experimental therapi[INVESTIGATOR_22750].
Diagnostic Assessments:
12. Baseline [ADDRESS_21811] participant safety or interpretation of study results (eg, QTc interval >[ADDRESS_21812] degree AV block, or serious bradyarrhythmias or tachyarrhythmias).  If the baseline uncorrected QT interval is >450 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting.  If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant’s eligibility.  Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
13. Participants with ANY of the following abnormalities in clinical laboratory tests at 
Screening, as assessed by [CONTACT_22797] a single repeat (the last value will be used to determine eligibility), if deemed necessary: 
a. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m
2;
b. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values 
≥[ADDRESS_21813]; 
c. Total bilirubin ≥1.[ADDRESS_21814]; participants with a history of Gilbert's 
syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤ULN.
[COMPANY_003]
PF-[ADDRESS_21815] interpretation of study data or the participant’s participation in the study.
Other Exclusions:
15. Investigator site staff or [COMPANY_007] employees directly involved in the conduct of the 
study, site staff otherwise supervised by [CONTACT_093], and their respective family members.
16. A history of alcohol or substance abuse within 6 months prior to Screening that in the 
opi[INVESTIGATOR_22751].
17. In the opi[INVESTIGATOR_22752], 
the participant is inappropriate for entry into this study.
5.3. Lifestyle Considerations
5.3.1. ContraceptionThe investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual participant and his or her partner(s) from the permitted list of contraception methods (see Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use acceptable effective contraception consistently and correctly and document the conversation and the participant’s affirmation in the participant’s chart (participants need to affirm their consistent and correct use of at least 1 of the permitted methods of contraception).  In addition, the investigator or designee will instruct the participant to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant or partner.
5.3.2. Dietary Supplements
For the purposes of this protocol, dietary supplements are defined as vitamins, minerals, 
purified food substances, and herbals with pharmaceutical properties.  Vitamins, minerals and purified food substances are allowed in amounts not known to be associated with adverse effects (such as hypervitaminosis). Herbals supplements are only allowed on a case by [CONTACT_413]; please contact [CONTACT_22798].  Herbals eg, St. John’s Wort that are known to have an 
effect on drug metabolism must be discontinued at least 4 weeks or 5 half-lives (whichever is 
longer) before Day 1. 
5.3.3. Medications/Treatments Discontinuation, Non-Medicated Emollients
Participants are required to discontinue and avoid using certain medications and treatments as 
described in Section 10.10 Appendix 10 . Prohibited Prior and Concomitant Medications
including medications which may result in Drug-Drug Interaction (DDI).  
[COMPANY_003]
PF-[ADDRESS_21816] be discontinued for the duration of the study, if the skin areas are to be treated with IP.  
Unless specified in Appendix 10 , any other concomitant medication for AD or psoriasis will 
be considered on a case by [CONTACT_22799].
Non-medicated emollient and sunscreen are the only topi[INVESTIGATOR_22753]. Participants will stop applying non-medicated emollient and sunscreen on atopic dermatitis/psoriatic skin 24 hours prior to Day 1/Randomization.  During the study treatment period, use of non-medicated emollient and sunscreen are allowed only on skin that was considered normal or non-lesional at Day 1 (ie, never treated with IP).  Any non-medicated emollient used by [CONTACT_22800] (CRF). 
Low or least potent (Class 6 or 7) topi[INVESTIGATOR_11930] (Hydrocortisone ≤1% and 
hydrocortisone acetate ≤1%) are the only topi[INVESTIGATOR_22754] (eg, palms, soles, face, and intertriginous).  Scalp tar preparations, salicylic acid preparations and shampoos free of corticosteroids are permitted for the treatment of scalp.  
Due to the potential to affect atopic dermatitis and psoriasis with ultraviolet light exposure, 
participants must avoid prolonged exposure to the sun and avoid the use of tanning booths, sun lamps or other ultraviolet light sources during the study. Please see Appendix 10 for 
details on prohibited light therapy.
5.3.4. Other Lifestyle Requirements
•Participants should not apply occlusive dressing(s) to the areas treated with IP. 
•Participants should not swim, bathe, be bathed or have treatment areas washed for at 
least 4 hours after application of the IP. 
•Use of sunscreen and regular moisturizes is permitted, but only on areas which are 
not treated with IP. 
•The participant should avoid wipi[INVESTIGATOR_22755]-applied to areas that were inadvertently wiped until the next scheduled dose.
•Participants will agree to avoid strenuous exercise during the study, especially within 
[ADDRESS_21817] 2020 
PFIZER CONFIDENTIAL
Page 48•On study visit days, the participants will not smoke or use nicotine-containing 
products, or ingest caffeine (eg, tea, coffee, some soft drinks/colas/energy drinks and power bars) during the 2 hours prior to blood pressure and pulse (heart) rate measurements.
•On study visit days, showering or bathing is permitted prior to attending the study 
visit, but moisturizing will not be done. 
•On study visit days, prescribed permitted concomitant medication will be taken, as 
needed, prior to the study visit, if it can be administered with water only.
•The participants will contact [CONTACT_22801].
•The participants will avoid having major elective surgery until after the final study 
assessments.
•The participants should continue all non-pharmacological therapi[INVESTIGATOR_014], such as physical 
therapy, as indicated.  However, the participants should avoid changing the type or intensity of therapy or initiating new therapy until after Week 6 visit.
•When applying the IP, the participant will not be required to wear gloves.  However, 
participants should be instructed to wash their hands with mild soap and water before and after each application. 
•If study participants need someone else to assist with applying investigational product 
on hard to reach areas (eg back), this person must wear gloves to avoid accidental exposure to the IP. 
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomly assigned to study intervention. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
re-screened once if they fail the screening evaluation for reasons related to incidental 
transitory conditions, unless the reason for the screen failure is the disease severity inclusion criteria. Participants may not be rescreened unless approved by [CONTACT_456]. Rescreened participants should be assigned a new participant number.
[COMPANY_003]
PF-[ADDRESS_21818] 2020 
PFIZER CONFIDENTIAL
Page 496. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study procedure(s) intended to be administered to a study participant according to the study protocol.
For the purposes of this protocol, study intervention refers to PF-07038124 0.01% ointment 
and PF-07038124 vehicle ointment (placebo).
6.1. Study Intervention Administered
Intervention Name [INVESTIGATOR_16335]-07038124 0.01% ointment PF-07038124 vehicle ointment
ARM Name
(group of patients receiving a specific treatment (or no treatment)Participants with mild or 
moderate AD, or mild or moderate psoriasisParticipants with mild or 
moderate AD, or mild or moderate psoriasis
Type Drug Drug
Dose Formulation Ointment Ointment
Unit Dose Strength(s) 0.1 mg/g ointment in 60-gram 
tube0 mg/g ointment in 60-gram 
tube
Dosage Level(s) 0.01% (wt/wt), QD 0% (wt/wt), QD
Route of Administration Topi[INVESTIGATOR_22756].Provided centrally by [CONTACT_103].
Packaging and Labeling Study intervention will be 
provided in cartons.  Each carton will contain one tube.  Both the 
carton and tube will be labeled 
in a blinded format as required per country requirement.Study intervention will be 
provided in cartons.  Each carton will contain one tube.  
Both the carton and tube will 
be labeled in a blinded format as required per country requirement.
6.1.1. Administration
[IP_ADDRESS]. Treatable AreasAD treatable areas will be all areas affected by [CONTACT_22802], except scalp.
Psoriasis treatable areas will be all areas affected by [CONTACT_22803], except scalp and nails.
[COMPANY_003]CCI
PF-[ADDRESS_21819] 2020 
PFIZER CONFIDENTIAL
Page 50A thin layer of IP ointment will be applied at a target application rate of approximately 
3 mg/cm2by [CONTACT_2329] a fingertip unit (FTU) method.
Day 1 VisitAt the Day 1 Visit, before the Day 1 initial IP application is performed, the designated areas 
for treatment will be identified and documented in the participant’s source document study records (body map). The participant and/or caregiver will be provided with a paper version of 
the body map. 
On Day 1 through the final dose at Week 6 visit, the IP should be applied once daily (around 
same time of the day), to all treatable AD or psoriasis involved areas identified at the Day 1 visit. 
All participants will be supplied with instructions on application and dose frequency 
commensurate to assigned treatment arm. Those participants having difficulty reaching treatment-eligible areas (eg, back) may be assisted by [CONTACT_22804]. The person assisting with the application must wear gloves to avoid any exposure to the IP. 
Participants and/or caregivers will be encouraged to observe and participate in the initial IP 
application on Day 1. 
Post Day 1 VisitsAfter Day 1/Randomization, all subsequent doses will be applied at home except the dose on 
the days of in-clinic visits.  
 The last dose of 
IP will be applied during the Week 6 in-clinic visit (EOT visit) as specified in Section 1.3.3
of the SoA.
The participant and/or caregiver will be instructed to complete the Dosing Diary starting with 
the first dose applied in the clinic on Day 1 through Week 6 (each time IP is applied) for all IP doses applied. If a participant misses applying a dose, the participant should apply this dose provided this dose should have been applied within the last [ADDRESS_21820] Day 1, any new AD or psoriasis on treatment-eligible areas identified by [CONTACT_22805](s) should also be treated with the IP. Decision to apply the IP to new eligible areas should be made following assessment by [CONTACT_21438]/her designee. An unscheduled visit for assessment of the new lesion may be required at the discretion of the investigator. Body map will be updated, and IP need will be re-assessed at every site visit during the treatment period. If the total, treatable BSA exceeds 20% (AD) or 15% (psoriasis) during the six-week treatment period, the participant will still remain eligible for the study, given that the total, treatable BSA does not exceed 22% (for AD) or 16.5% (for psoriasis). If the total, treatable BSA exceeds 22% (AD) or 16.5% (psoriasis), the Sponsor may decide to discontinue the participant.
Participants and/or caregivers will be instructed not to wipe investigational product off the 
skin, avoid applying an occlusive dressing to the treated areas, and refrain from swimming or bathing/washing the treated areas within 4 hours after application.
Under no circumstances will the investigational drug application regimen be modified 
(eg, frequency of application increased or reduced, not stopped, or the application rate [target 3 mg/cm
2] increased or reduced) during the study. Temporary discontinuation of 
investigational drug may be appropriate under some circumstances (eg, surgery, non-serious infections) and should be discussed with the Medical Monitor (or designee) preferably prior to temporary discontinuation of investigational drug.
Study intervention administration details will be recorded on the CRF.6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.  At a minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperatures since previously documented for all site storage locations upon return to business.
3. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery along with any actions taken.  The site should actively pursue options for returning the study intervention to the storage conditions described in the labeling, as soon as possible.  Once an excursion is identified, the study intervention must be quarantined and not used until [COMPANY_007] provides permission to use the study intervention.  Specific details regarding the definition of an excursion 
[COMPANY_003]
PF-[ADDRESS_21821] participants on the proper storage requirements for take-home 
study intervention.
7. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record.  All study intervention that is taken home by [CONTACT_2299], both used and unused, must be returned to the investigator by [CONTACT_2299].  Returned study intervention must not be redispensed to the participants.
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the IP manual. All destruction must be adequately documented.  If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery as described in the IP Manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the IP ready for application or dispensing to the participant/caregiver by [CONTACT_3436].
Dispensing is defined as the provision of IP, concomitant treatments, and accompanying 
information by [CONTACT_22806](s) to a healthcare provider, participant, or caregiver in accordance with this protocol. Local health authority regulations or investigator site guidelines may use alternative terms for these activities.
The IP will be dispensed in a blinded fashion using an interactive response technology (IRT) 
system at Day 1/Baseline, Week 1, Week 2 and Week 4 visits. A qualified staff member will dispense the IP via unique container numbers on the cartons provided, in quantities appropriate for the study visit schedule and the treatable % BSA.
[COMPANY_003]
PF-[ADDRESS_21822] and its original package (including empty, partial used and unused tubes) to the site at the next study visit. 
IP will be assigned to participants at the Day 1 visit once the participant is successfully 
randomized through the IRT system. The investigator, appropriate delegate or site personnel will access the IRT system at screening and all subsequent IP dispensing visits to enter information including, but not limited to, the participants height, weight and % affected BSA to receive correct tube numbers to be dispensed to the participant. Alternatively, the tool to standardize the IP need calculation across participants and study sites may be provided by [CONTACT_456].
The calculation of treatable BSA is described in Section [IP_ADDRESS] and Section [IP_ADDRESS] for AD 
and psoriasis respectively.
All tubes of investigational product dispensed or returned will be recorded and documented.6.2.2. Investigational Product Accountability
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the IP supplies. All investigational products will be accounted for using a drug accountability form/record. All tubes of the IP must be returned to the investigator by [CONTACT_22807].
The participant will be asked to bring all dispensed IP (including empty, partially used and 
unused tubes) at every ‘compliance check’ visit; participants will be asked to bring dosing diary to the clinic at every clinic visit. All previously dispensed IP tubes will be retained by [CONTACT_779]. For each participant, IP tubes with caps will be weighed individually or collectively by [CONTACT_22808]. The sponsor will use the recorded weights to estimate usage (eg, mg/cm
2/application) for each 
participant. Note that the weight recorded on the IP label is a nominal weight and not an exact weight of the IP and tube. Detailed drug accountability records, including tube weights measured in the clinic, will be maintained by [CONTACT_22809].
The original IP accountability log, or equivalent document, must be accurately completed, 
signed by [CONTACT_737], and retained at the study site (with a copy supplied to the Sponsor) when the study is complete.
6.2.3. Destruction of Investigational Product Supplies
For all IP returned to the investigator by [CONTACT_2299], the investigator will maintain the 
returned supply until destruction is authorized.
[COMPANY_003]
PF-[ADDRESS_21823] (eg, at the site). If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618], and all destruction must be adequately documented.
Further guidance and information for the final disposition of unused study interventions are 
provided in the IP manual.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study InterventionAllocation of participants to treatment groups will proceed through the use of an IRT system 
(IWR).  The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user’s ID and password, the protocol number, and the participant number.  The site personnel will then be provided with a treatment assignment, randomization number, and DU or container number when study intervention is being supplied via the IRT system.  The IRT system will provide a confirmation report containing the participant number, randomization number, and DU or container number assigned.  The confirmation report must be stored in the site’s files. 
Study intervention will be dispensed at the study visits summarized in the SoA. 
Returned study intervention must not be redispensed to the participants.The study-specific IRT reference manual and IP manual will provide the contact [CONTACT_22810].
6.3.2. Breaking the Blind 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact [CONTACT_22811]’s treatment assignment unless this could delay further management of the participant. However, discussion with the Sponsor in advance of unblinding is not required. If a participant’s treatment assignment is unblinded, the sponsor must be notified within 
[ADDRESS_21824] 2020 
PFIZER CONFIDENTIAL
Page 556.4. Study Intervention Compliance
The participant and/or a caregiver will apply IP at home or during in-clinic visits as specified 
in the SoA.  The participant and/or caregiver will be instructed to complete the Dosing Diary 
starting with the first dose applied in the clinic on Day 1 through Week 6 (each time IP is applied) for the IP doses applied at home.  Participants will be instructed to refrain from dosing at home on the day of the in-clinic visit, and are to bring to the clinic all used, partially used and empty IP tubes in their original containers for weighing, at each visit. 
Participant compliance with IP will be assessed on visits identified in the SoA. Compliance 
will be assessed by [CONTACT_22812]/caregiver completed Dosing Diary and by [CONTACT_22813].  The difference in weight(s) of the returned IP tubes will be used to estimate the doses applied.  Source documents will be placed in the participant’s study file.  Deviation(s) from the prescribed dosage regimen should be recorded in the CRF.
From Day 1 through Week 6 visit, non-compliance is defined as less than 80% or more than 
120% of IP applications.  If non-compliance is identified, or even if a few dose applications are missed or over-applied, then, participants will be re-trained on the importance and the process of proper IP application.  If non-compliance persists, the investigator, in consultationwith the Sponsor, may withdraw any participant from the study for reasons of non-compliance with the dosing regimen.  Investigators should indicate on the appropriate CRF page noncompliance with study intervention and provide an explanation. 
Inventory control of all IPs must be rigorously maintained throughout the duration of the 
study until all medication has been accounted for and/or returned to the sponsor.  Any discrepancies noted between drug dispensing records and the drug inventory must be reported to [COMPANY_007].
6.5. Concomitant Therapy
All prior medications including non-medication therapi[INVESTIGATOR_014], as well as biologic drugs used for 
AD or psoriasis within [ADDRESS_21825] be recorded in study records with indication, daily dose, and start and stop dates of 
administration.  Participants will be queried about concomitant medication (including topi[INVESTIGATOR_22757], over the counter and prescription medications and treatments, and vaccinations) at each visit.  Any new concomitant medications or dose changes to current concomitant medications should be evaluated for potential new or worsening AEs. 
Refer to Appendix [ADDRESS_21826] be stopped.  
Hormonal contraceptives that meet the requirements of this study are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
[COMPANY_003]
PF-[ADDRESS_21827] 2020 
PFIZER CONFIDENTIAL
Page 56Concomitant medications for other stable chronic medical conditions are permitted during 
the study unless the medication/therapy is specifically prohibited by [CONTACT_22814]. Nonsteroidal anti-inflammatory drugs are allowed throughout the study. 
Routine preventative immunizations are permitted during the study; however, it is preferred 
that immunizations be administered at least [ADDRESS_21828]’s participation in study. Vaccines used in the event of a disease outbreak or pandemic are allowed.
6.5.1. Rescue Medicine
There is no rescue therapy to reverse the AEs observed with PF-07038124; standard medical 
supportive care must be provided to manage the AEs. 
6.6. Dose Modification
Not applicable.
6.7. Intervention After the End of the Study
No intervention will be provided to study participants at the end of the study.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIn rare instances, it may be necessary for a participant to permanently discontinue study 
intervention (definitive discontinuation).  Reasons for definitive discontinuation of study intervention include the following: Liver injury, ECG changes, pregnancy, local tolerability, and AEs.  
Note that discontinuation of study intervention does not represent withdrawal from the study.  
If study intervention is definitively discontinued, the participant will proceed to ET and remain in the study to be evaluated for follow up visits.  See the SoA for data to be collected 
at the time of discontinuation of study intervention and follow-up for any further evaluations that need to be completed. The site will inform the Sponsor Medical Monitor or Sponsor clinician if the below criteria for permanent discontinuation of the study intervention are triggered.
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of study intervention or also from study procedures, posttreatment study follow-up, and/or future collection of additional information.
[COMPANY_003]
PF-[ADDRESS_21829] 2020 
PFIZER CONFIDENTIAL
Page 57Liver Injury
Please refer to Section 10.6 Appendix 6 for Potential Cases of Drug-Induced Liver Injury 
(DILI; Hy’s law).
ECG ChangesA participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study intervention. 
•QTcF >500 msec.
•Change from baseline: QTcF >60 msec.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if the participant can continue in the study and if any change in participant management is needed.  This review of the ECG printed at the time of collection must be documented.  Any new clinically relevant finding should be reported as an AE.
Pregnancy
Pregnancy confirmed by [CONTACT_11084] β-hCG testing.  Sponsor Clinician or Sponsor Medical 
Monitor should be notified immediately.
Two negative pregnancy tests are required before randomization ([ADDRESS_21830] at Day 1 visit).  If urine 
pregnancy test is positive after study intervention application, serum pregnancy test will be 
conducted, study intervention application paused and sponsor clinician and sponsor medical monitor notified immediately.
Local Tolerability If a participant experiences severity Grade 3 (severe) or 4 (very severe) on the local 
tolerability assessment ( Section 8.2.7 ), study treatment will be discontinued permanently, and 
participant will proceed to ET visit and follow-up as described in SoA. 
If a participant experiences application site reaction of Grade 2 (moderate) on the local 
tolerability assessment, investigator may temporarily discontinue application of IP for up to [ADDRESS_21831] 2020 
PFIZER CONFIDENTIAL
Page 58AEs
Hypersensitivity Reactions: If signs and symptoms of hypersensitivity are attributable to the 
investigational product, including contact [CONTACT_22815], it must be discontinued immediately, and appropriate therapy initiated. 
7.1.1. Temporary Discontinuation
Temporary discontinuations of IP 
•Will occur in cases of positive urine pregnancy test which if confirmed by [CONTACT_22816] ( Section 7.1 ). 
•May apply in some cases application site reaction during local tolerability 
assessments ( Section 8.2.7 ). 
•Additional instances of temporary discontinuation may be appropriate (eg, surgery, 
infection, etc). 
All temporary discontinuations should be discussed with Sponsor Clinician or Sponsor 
Medical Monitor to determine if participant may continue in the study.  If possible, site will consult sponsor prior to temporary discontinuation.
7.1.2. RechallengeNot applicable.7.2. Participant Discontinuation/Withdrawal from the Study
A participant may withdraw from the study at any time at his/her own request.  Reasons for 
discontinuation from the study include the following:
•Refused further follow-up;
•Lost to follow-up;
•Death;
•Study terminated by [CONTACT_3211].
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study.  Participants should be questioned regarding their reason for withdrawal. The participant will be permanently discontinued both from the study intervention and from the study at that time.
[COMPANY_003]
PF-[ADDRESS_21832] 2020 
PFIZER CONFIDENTIAL
Page 59If a participant withdraws from the study, he/she may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1 ) 
for disclosure of future information, no further evaluations should be performed and no additional data should be collected.  The sponsor may retain and continue to use any data collected before such withdrawal of consent.
Lack of completion of all or any of the withdrawal/early termination procedures will not be 
viewed as protocol deviations so long as the participant’s safety was preserved.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol-specified follow-up procedures.  The only exception to this is when a participant specifically withdraws consent for any further contact [CONTACT_22817].  Participants should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible.  The withdrawal of consent should be explained in detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from further receipt of study intervention or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page.  In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.
7.3. Lost to Follow-up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:
•The site must attempt to contact [CONTACT_22818]/or should continue in the study;
•Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record;
[COMPANY_003]
PF-[ADDRESS_21833] 2020 
PFIZER CONFIDENTIAL
Page 60•Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures.  
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety issues should be discussed with the sponsor immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons forscreening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA.
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform the test.  In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant.  When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that he or she has taken to ensure that required processes are adhered to as soon as possible.  The study team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].
The total blood sampling volume for individual participants in this study is approximately
[ADDRESS_21834] 2020 
PFIZER CONFIDENTIAL
Page 618.1. Efficacy Assessments
8.1.1. Rater QualificationsFor specific rating assessments, only qualified raters will be allowed to evaluate and/or rate 
participants in this study.  The minimum qualifications a rater must meet for each study rating assessment will be outlined in the Rater Assessment Guide provided to eachparticipating site.  The level of experience with the target population (or equivalent), specific scale experience (or equivalent), and certification required (if applicable) will be listed andused to determine whether a rater is approved for a given assessment.  Proposed raters who do not meet specific criteria but who may be qualified based on unique circumstances may be individually reviewed by [CONTACT_22820] a waiver may be issued.  The rater must become certified to perform selected study assessments before he or she can participate in the conduct of the study.  For specifically defined assessments, rater training and standardization exercises may be conducted, and written and signed documentation will be provided by [CONTACT_22821]’s certification.  In return, each site will be provided written and signed documentation outlining each rater’s certification for specific study assessments.  Recertification may be required at periodic intervals during the study.  The raters who administer specific study assessments will be documented in a centralized location and all site staff who administer ratings will be verified in the site study documentation during the conduct of the study.
EFFICACY ASSESSMENTS FOR AD
All efficacy assessments will be based on areas treated with IP, and excluding scalp, palms 
and soles from the assessment/scoring.
8.1.2. Physician Assessments for AD
[IP_ADDRESS]. Eczema Area and Severity Index (EASI)
The EASI quantifies the severity of a participant’s AD based on both severity of lesion by 
[CONTACT_22822].  EASI is a composite scoring of the degree of erythema, induration/papulation, excoriation, and lichenification (each scored separately) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body.
8
Lesion Severity by [CONTACT_22823] (erythema, induration/papulation, excoriation, and 
lichenification) provide a means for assessing the severity of lesions.  Assessment of these four main clinical signs is performed separately for four body regions: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks).  Average erythema, induration/papulation, excoriation, and lichenification are scored for each body region according to a 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe.  Morphologic descriptors for each clinical sign severity score are shown in Table [ADDRESS_21835] 2020 
PFIZER CONFIDENTIAL
Page 62Table 5. Clinical Sign Severity Scoring Criteria for EASI
Score Description
Erythema (E)
0 AbsentNone; may have residual discoloration (post-inflammatory hyperpi[INVESTIGATOR_22758]/or 
hypopi[INVESTIGATOR_371])
1 Mild Light pi[INVESTIGATOR_22759]
2 Moderate Red
3 Severe Deep, dark red
Induration/Papulation (I)
[ADDRESS_21836] thickened skin and/or papules
[ADDRESS_21837] thickened skin and/or papules
[ADDRESS_21838] thickened skin and/or papules
Excoriation (Ex)
0 Absent None
1 Mild Slight, but definite linear or pi[INVESTIGATOR_22760]
2 Moderate Moderate linear or pi[INVESTIGATOR_22760]
3 Severe Severe linear or pi[INVESTIGATOR_22761] (L)
0 Absent None
1M i l dBarely perceptible to slight, but definite thickened skin, fine skin markings, and 
lichenoid scale
2 Moderate Moderate thickened skin, coarse skin markings, and coarse lichenoid scale
3 Severe Severe thickened skin with very coarse skin markings and lichenoid scale
* The EASI will exclude scalp, palms and soles from the assessment/scoring.
BSA with AD for EASI Assessment (excluding scalp, palms and soles)
BSA affected by [CONTACT_22824], ie, head and neck 
(h), upper extremities (u), trunk (t), and lower extremities (l).  The area within each body region with the key signs of the disease is estimated using handprint as a measure, where the full palmar hand of the participant (ie, the participant’s fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA.
Each region is typi[INVESTIGATOR_22762] 10 (h), 20 (u), 30 (t), 
and 40 (l) handprints respectively.  Refer to Table [ADDRESS_21839] 2020 
PFIZER CONFIDENTIAL
Page 63Table 6. Handprint Determination of Body Region Surface Area for AD
Body RegionTotal Number of Handprints 
in Body RegionSurface Area of Body 
Region Equivalent of One 
Handprint
Head and Neck 10 10%
Upper Limbs 20 5%
Trunk (including axillae and groin) 30 3.33%
Lower Limbs (including buttocks) 40 2.5%
Area Score
The extent (%) to which each of the four body regions is involved with AD (by [CONTACT_22825] 6
above) is categorized using a non-linear scaling method to a numerical area score according to the following BSA scoring criteria (Table 7).
Table 7. EASI Area Score Criteria
Percent BSA with AD in a Body Region Area Score
0% 0
>0-<10% 1
10-<30% 2
30-<50% 3
50-<70% 4
70-<90% 5
90-100% 6
Body Region WeightingEach body region is weighted according to its approximate percentage of the whole body 
(Table 8). 
Table 8. EASI Body Region Weighting
Body Region Body Region Weighting
Head and Neck 0.1
Upper Limbs 0.2
Trunk (including axillae and groin) 0.3
Lower Limbs (including buttocks) 0.4
Calculation of EASI Score 
In each body region, the sum of the Clinical Signs Severity Scores for erythema, 
induration/papulation, excoriation, and lichenification is multiplied by [CONTACT_22826] a body region value, which is then summed across all four body regions resulting in an EASI score as described in the following equation.
[COMPANY_003]
PF-[ADDRESS_21840] 2020 
PFIZER CONFIDENTIAL
Page 64EASI = 0.1Ah(E h+Ih+Ex h+Lh) + 0.2Au(E u+Iu+Ex u+Lu) + 0.3At(E t+It+Ex t+Lt) + 
0.4Al(E l+Il+Ex l+Ll)
A = Area Score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; 
h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores 
representing greater severity of AD. Since the scalp, palms and soles will be excluded from the EASI assessment in this study (even if palms and soles are being treated with the IP), the maximum possible score will be less than 72.0.
[IP_ADDRESS]. Investigator’s Global Assessment (IGA)
The IGA of AD is scored on a 5-point scale ra nging from 0 (clear) to 4 (severe), reflecting a 
global consideration of the erythema, induration and scaling.  The clinical evaluator of AD will perform an assessment of the overall severity of AD and assign an IGA score and category as described below. The assessment will be a static evaluation without regard to the score at a previous visit. 
Table 9. Investigator’s Global Assessment (IGA) Score
Score Category Description*
0 ClearAtopic dermatitis (AD) is cleared, except for any residual discoloration 
(post-inflammatory hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_371]).
[ADDRESS_21841] ClearOverall, the AD is not entirely cleared and remaining lesions are light pi[INVESTIGATOR_8745] (not 
including post inflammatory hyperpi[INVESTIGATOR_371]) and/or; have barely palpable 
hard thickened skin and/or papules and/or; have barely perceptible 
lichenification; excoriation and oozing/crusting are absent.
2 MildOverall, the AD consists of lesions that are light red; with slight, but definite 
hard thickened skin and/or papules; with slight, but definite linear or pi[INVESTIGATOR_22763]; with slight, but definite thickened skin, fine skin markings, and lichenoid scale; oozing/crusting is absent.
3 ModerateOverall, the AD consists of lesions that are red; with easily palpable moderate 
hard thickened skin and/or papules; with moderate linear or pi[INVESTIGATOR_22760]; with moderate thickened skin, coarse skin markings, and coarse lichenoid scale; with slight oozing/crusting.
4 SevereOverall, the AD consists of lesions that are deep, dark red; with severe hard 
thickened skin and/or papules; with severe linear or pi[INVESTIGATOR_22760]; with severe thickened skin with very coarse skin markings and lichenoid scale; with moderate to severe oozing/crusting.
* The IGA will exclude scalp, palms, and soles from the assessment/scoring.
[COMPANY_003]
PF-[ADDRESS_21842] 2020 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. BSA with AD
Assessment of BSA involved in AD is performed separately for four areas of the body: head
(including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks).  The percentage surface area affected by [CONTACT_22827] “handprint method”, where the full hand of the participant (ie, the participant’s fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA.Refer to Table 6 to identify the surface area equivalent of 1 handprint in each respective body 
region.
Body region value is then summed across all four body regions resulting in a total BSA with 
AD as described in the following equation:
BSA (%) =0.1Sh + 0.2Su + 0.3St + 0.4Sl
where S = body region surface area with AD; h = head & neck; u = upper limbs; t = trunk; l = lower limbs. 
BSA with AD for Efficacy Assessment (Efficacy BSA)BSA with AD for efficacy evaluation excludes scalp, palms, and soles.
BSA with AD for IP Need (Treatable BSA)
Evaluation of BSA for IP need is the total BSA across all body locations being treated with 
the IP.  BSA for IP need evaluation method will be the same as the BSA with AD for efficacy assessment, except that the BSA for IP need will include AD on all IP treated body locations (including palms and soles but not scalp).  If a participant has AD on palms, and/or soles, these body locations will be included in the BSA for IP need estimation.
Investigational product should be applied to the BSA determined at Day [ADDRESS_21843] of body site areas currently aff ected by [CONTACT_22802] (body map) will be completed at the 
Day 1 visit.  The body map will be reviewed at every visit to the site to update for any new, treatable areas, if needed.
8.1.3. Patient Reported Outcome Measures for AD
Every effort should be made for the participant to complete all patient reported outcome
(PRO) questionnaires before any other evaluations. The amount of time required for participants to complete the PRO questionnaires is approximately 10-30 minutes (depending on the visit and associated PROs). The PROs should be checked for completeness by [CONTACT_22828]-clinic visit.
[COMPANY_003]
PF-[ADDRESS_21844] 2020 
PFIZER CONFIDENTIAL
Page 66Participants will be provided a handheld device (provided by [CONTACT_1034]) for dosing diary 
and electronic patient-reported-outcomes (ePROs) or paper versions of the above to be completed at home as per the time points defined in the SoA. The clinic sites may use paper 
versions of PROs.
The following PROs will be completed only on study visit days identified in SoA, 
PP-NRS will be used by [CONTACT_22829], starting from the 
screening visit or at least 7 days prior to the dosing/randomization day (Day 1) and as defined in the SoA.
All participants will complete PROs at follow-up visit in clinic.Delegated site staff will monitor completion of PROs for adherence and will review 
adherence with participants at each visit and counsel as appropriate. If a participant has repeated non-adherence, the participant should be retrained on use of the device or filling out paper versions. If a participant is unable to complete ePROs due to documented technical issue or disability or other limitation, the participant will be permitted to enter or remain in the study providing that a valid alternate source of daily data entry is completed and reviewed by [CONTACT_22830]. No protocol deviations will be recorded in regard to PRO completion adherence. In the event of electronic malfunction of an ePRO ormisplacement of paper versions of the PROs, a replacement device or paper PROs will be shipped to the site. 
[IP_ADDRESS]. Peak Pruritus Numerical Rating Scale (PP-NRS) for AD
The PP-NRS is a daily patient-reported assessment of intensity of pruritus on an 11-point 
numerical rating scale, ranging from 0 (‘No Itch) to 10 (‘Worst Itch Imaginable’) with a 24-hour recall period.
[ADDRESS_21845] 2020 
PFIZER CONFIDENTIAL
Page 67EFFICACY ASSESSMENTS FOR PSORIASIS
All efficacy assessments of psoriatic skin will be based only on areas treated with IP and 
excluding scalp, palms, soles, nails from the assessment/scoring.
8.1.4. Physician Assessments for Psoriasis
[IP_ADDRESS]. Psoriasis Area and Severity Index (PASI)
PASI quantifies the severity of a participant’s psoriasis based on both lesion severity and the 
percentage of body surface area affected.11
Lesion Severity Score
The basic characteristics of psoriatic lesions (erythema, induration and scaling) provide a 
means for assessing the severity of lesions.  Assessment of these three main signs is performed separately for four areas of the body: head, upper limbs, trunk, and lower limbs.  Average erythema, induration and scaling are rated for each body area according to a 5-point 
scale: 0, no involvement; 1, slight; 2, moderate; 3, marked; 4, very marked.  Appropriate 
morphologic descriptors for each severity score are shown in Table [ADDRESS_21846] 2020 
PFIZER CONFIDENTIAL
Page 68Table 10. Component Scoring Criteria for PASI*
Component Score Description
Erythema (E)
0 No involvement None; may have residual hyperpi[INVESTIGATOR_371]
1 Slight Pi[INVESTIGATOR_22764]
2 Moderate Darker pi[INVESTIGATOR_8745]-red
3 Marked Red
4 Very Marked Extremely red, “beefy” red
Induration (I)
[ADDRESS_21847], sharp borders
Scaling (S)
[ADDRESS_21848] lesions partially covered
3 Marked Coarser thick scale, nearly all lesions covered, rough
4 Very Marked Very thick scale, all lesions covered, very rough
* The PASI will exclude scalp, palms, soles, nails from the assessment/scoring.
BSA with Psoriasis for PASI Assessment (excluding scalp, palms, soles and nails)
BSA affected by [CONTACT_22831], head and 
neck (h), upper extremities (u), trunk (t), and lower extremities (l).  The area within each body region with the key signs of the disease is estimated using handprint as a measure, where the full palmar hand of the participant (ie, the participant’s fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA.
Each region is typi[INVESTIGATOR_22762] 10 (h), 20 (u), 30 (t), 
and 40 (l) handprints respectively.  Refer to Table 11 to identify the surface area equivalent of 1 handprint in each respective body region.
Table 11. Handprint Determination of Body Region Surface Area for Psoriasis
Body RegionTotal Number of Handprints 
in Body RegionSurface Area of Body 
Region Equivalent of One Handprint
Head and Neck 10 10%
Upper Limbs 20 5%
Trunk (including axillae and groin) 30 3.33%
Lower Limbs (including buttocks) 40 2.5%
[COMPANY_003]
PF-[ADDRESS_21849] 2020 
PFIZER CONFIDENTIAL
Page 69Area Score
The extent (%) to which each of the four body regions is invol ved with psoriasis (by [CONTACT_22832] 11 above) is categorized using a non-linear scaling method to a numerical area score 
according to the following BSA scoring criteria (Table 12).
Table 12. PASI Area Score Criteria
Percent BSA with psoriasis in a Body 
RegionArea Score
0% 0
>0-<10% 1
10-<30% 2
30-<50% 3
50-<70% 4
70-<90% 5
90-100% 6
Body Region WeightingEach body region is weighted according to its approximate percentage of the whole body 
(Table 13).
Table 13. PASI Body Region Weighting
Body Region Body Region Weighting
Head and Neck 0.1
Upper Limbs 0.2
Trunk (including axillae and groin) 0.3
Lower Limbs (including buttocks) 0.4
Calculating of PASI score
In each body region, the sum of the Severity Scores for erythema, induration and scaling is 
multiplied by [CONTACT_22826] a body region value, which is then summed across all four body regions resulting in a PASI score as described in the following equation:
PASI = 0.1Ah(E
h+Ih+Sh) + 0.2Au(E u+Iu+Su) + 0.3At(E t+It+St) + 0.4Al(E l+Il+Sl)
A = Area Score; E = erythema; I = induration/papulation; S=scaling; h = head and neck; u = upper limbs;
t = trunk; l = lower limbs.
The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0*, with higher scores 
representing greater severity of psoriasis.  
*Since the scalp, palms, soles and nails will be excluded from the PASI assessment in this 
study (even if palms and soles are being trea ted with the IP), the maximum possible score 
will be less than 72.0.
[COMPANY_003]
PF-[ADDRESS_21850] 2020 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Physician Global Assessment 
The Physician Global Assessment (PGA) of psoriasis is scored on a descriptive 5-point 
scale.12  The 5-point scale for PGA is: 0, “clear”; 1, “almost clear”; 2, “mild”; 3, “moderate”; 
4 “severe” (Table 14). The assessment will be a static evaluation without regard to the score at a previous visit.
Table 14. Physician Global Assessment (PGA) Score
Physician’s Global 
AssessmentDescription
0 Clear No signs of psoriasis; post-inflammatory hyperpi[INVESTIGATOR_22765]
[ADDRESS_21851] Clear No thickening; normal to pi[INVESTIGATOR_22766]; no to minimal focal scaling
[ADDRESS_21852] detectable to mild thickening; pi[INVESTIGATOR_22767]; predominantly fine 
scaling
3 ModerateClearly distinguishable to moderate thickening; dull to bright red, clearly 
distinguishable to moderate thickening; moderate scaling
[ADDRESS_21853] edges; bright to deep dark red coloration; severe/coarse
scaling covering almost all or all lesions
[IP_ADDRESS]. BSA with Psoriasis 
Assessment of body surface area (BSA) involved in psoriasis is performed separately for four 
areas of the body: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks).  The percentage surface area affected by [CONTACT_22833] “handprint method”, where the full hand of the participant (ie, the participant’s fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. Refer to Table 11 to identify the surface area equivalent of 1 handprint 
in each respective body region.
Body region value is then summed across all four body regions resulting in a total BSA with 
psoriasis as described in the following equation:
BSA (%) =0.1Sh + 0.2Su + 0.3St + 0.4Sl
where S = body region surface area with psoriasis; h = head & neck; u = upper limbs; t = trunk; l = lower limbs.
BSA with Psoriasis for Efficacy Assessment (Efficacy BSA)BSA with psoriasis for efficacy evaluation excludes scalp, palms, soles, and nails.BSA with Psoriasis for IP Need (Treatable BSA)Evaluation of BSA for IP need is the total BSA across all body locations being treated with 
the IP.  BSA for IP need evaluation method will be the same as the BSA with psoriasis for efficacy assessment, except that the BSA for IP need will include psoriasis on all IP treated body locations (including palms and soles but not scalp and nails).  If a participant has 
[COMPANY_003]
PF-[ADDRESS_21854] 2020 
PFIZER CONFIDENTIAL
Page 71psoriasis on palms, and/or soles, these body locations will be included in the BSA for IP need 
estimation.
Investigational product should be applied to the BSA determined at Day [ADDRESS_21855] of body site areas currently affected by [CONTACT_22803] (body map) will be completed at 
the Day 1 visit.  The body map will be reviewed at every visit to the site to update for any new, treatable areas, if needed.
8.1.5. Patient Reported Outcome Measures for Psoriasis
Every effort should be made for the participant to complete all patient reported outcome 
(PRO) questionnaires before any other evaluations. The amount of time required for participants to complete the PRO questionnaires is approximately 10-30 minutes (depending on the visit and associated PROs). The PROs should be checked for completeness by [CONTACT_22828]-clinic visit.
Participants will be provided a handheld device (provided by [CONTACT_1034]) for dosing diary
and electronic patient-reported-outcomes (ePROs) or paper versions of the above to be completed at home as per the time points defined in SoA. The clinic sites may use paper 
versions of PROs.
The following PROs will be completed only on study visit days identified in SoA, 
 PSI will 
be used by [CONTACT_22829], starting from the screening visit or at least 7 days prior to the dosing/randomization day (Day 1) and as defined in the SoA.
[IP_ADDRESS]. Psoriasis Symptom Inventory (PSI) for Psoriasis
PSI is a self-administered [ADDRESS_21856] 2 weeks up to Week 2 visit (inclusive), the PSI will als o be administered daily using a recall period of 
[ADDRESS_21857] 7 days. The measure includes concepts of itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Patients are asked to respond to each item using a 5-point Likert response scale: 0: not all severe, 1: mild, 2: moderate, 3: severe and 4: very severe. 
[COMPANY_003]CCI
PF-[ADDRESS_21858] 2020 
PFIZER CONFIDENTIAL
Page 728.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety issues.
8.2.1. Medical History
Investigators should make all reasonable efforts to obtain an accurate and complete medical 
history and history of prior medication use when evaluating whether a participant is eligible for the study.  The following will be collected at Screening: complete medical history, AD or psoriasis disease history (including disease duration and prior treatments) and alcohol and tobacco use history.
Complete AD or psoriasis disease history includes collection of details of AD or psoriasis at 
Screening: AD or psoriasis diagnosis, the use of topi[INVESTIGATOR_12969], systemic treatments and 
other treatments for AD or psoriasis taken during the 180 days prior to Screening with dose, 
duration of treatment, and reason for discontinuation.  All other drugs (including sunscreen, over the counter medication, vitamins, and dietary supplements) taken within [ADDRESS_21859] 2020 
PFIZER CONFIDENTIAL
Page 73Medical history in addition to AD or psoriasis history including disease duration will be 
collected at screening. Medical history also includes history of alcohol and tobacco use.  Smoking status and average weekly alcohol consumption (units/week) will be collected, where a unit contains 12 g of pure alcohol, an amount equivalent to that contained in 5 oz/150 mL (a glass) of wine, 12 oz/360 mL of beer, or 1.5 oz/45 mL of 90 proof of spi[INVESTIGATOR_2120]. 
If the status of a participant’s medical history is in doubt or information pertaining to a 
critical variable is conflicting, every reasonable step to secure proper documentation of correct medical status should be attempted.  Documentation of the medical and medication histories over the protocol defined time periods should be available for sponsor review during the source data verification process.  Questions about prior medications or eligibility should be directed to the Sponsor Clinician or Sponsor Medical Monitor.
Medical History will be collected at the Screening visit, and reviewed at Baseline Day 1 visit 
of any changes.
8.2.2. Physical Examinations (Including Height and Weight)
Physical examinations, including complete physical examination, targeted physical 
examination, height and weight will be performed at times specified in the SoA.
Physical examinations must be performed by [CONTACT_093], sub-investigator, or a qualified 
healthcare professional per local guidelines. Investigators should pay special attention to clinical signs related to previous serious illnesses.
A Complete physical examination will include, at a minimum, assessments of the general 
appearance, skin (presence of rash), HEENT (head, eyes, ears, nose and throat), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs), abdomen (palpation and auscultation), musculoskeletal (presence of peripheral edema), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination) and lymph nodes.
A Targeted physical examination consists of skin, heart, lungs, abdomen, and examination of 
body systems where there are symptom complaints by [CONTACT_3038].
It is recommended that weight be measured in kilograms (kg) to the nearest 0.1 kg and that 
height be measured in centimeters (cm) with shoes removed. 
For measuring weight, a scale with appropriate range and resolution is used and must be 
placed on a stable, flat surface.  Participants must remove shoes, bulky layers of clothing, and 
jackets so that only light clothing remains.  They must also remove the contents of their pockets and remain still during measurement of weight.
Please see Section 8.2.[ADDRESS_21860] 2020 
PFIZER CONFIDENTIAL
Page 748.2.3. Vital Signs
Temperature (oral or tympanic temperature), pulse rate, and blood pressure will be assessed.
Blood pressure and pulse rate measurements will be assessed with the participant in a supi[INVESTIGATOR_22768] a completely automated device.  Manual techniques will be used only if an automated device is not available. Blood pressure and pulse rate measurements should be preceded by [CONTACT_2669] [ADDRESS_21861] for the participant in a quiet setting without distractions (eg, television, cell phones).
Assessment of vital signs should precede blood draw for clinical laboratory visits.Body temperature will be collected using the tympanic or oral methods and the same method 
should be used consistently throughout the study. 
8.2.4. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the heart rate and measures PR, QT, and QTcF intervals and QRS complex. Alternative lead placement methodology using torso leads (eg, Mason-Likar) is not recommended given the potential risk of discrepancies with ECGs acquired using standard limb lead placement. All scheduled ECGs should be performed after the participant has rested quietly for at least [ADDRESS_21862] initial screening value QTcF >450 milliseconds (ms), 
ECG should be repeated two more times and the average of the three QTcF should be used to determine the participant eligibility.
To ensure safety of the participant, a qualified individual (eg, sub-investigator) at the 
investigator site will make comparisons to baseline measurements taken at Day 1. In the event of marked prolongation of the QTcF interval to >500 msec or >60 msec change from baseline (Day 1), the ECG should be repeated two more times and the average of the three QTcF should be used to determine the discontinuation of study intervention ( Section 7.1
Discontinuation of Study Intervention).
If a) a postdose QTcF interval remains ≥60 msec from the baseline andis >450 msec; or 
b) an absolute QTcF value is ≥500 msec for any scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator); or c) QTcF intervals get progressively longer, 
the participant should undergo continuous ECG monitoring.  A cardiologist should be 
consulted if QTcF intervals do not return to less than the criterion listed above after 8 hours of monitoring (or sooner, at the discretion of the investigator).
[COMPANY_003]
PF-[ADDRESS_21863] 2020 
PFIZER CONFIDENTIAL
Page 75In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads be placed in the same positions each time in order to achieve precise ECG recordings.  If a machine-read QTcF value is prolonged, as defined above, repeat measurements may not be necessary if a qualified medical provider’s interpretation determines that the QTcF values are in the acceptable range.
ECG values of potential clinical concern are listed in Appendix [ADDRESS_21864] any 
clinically relevant changes occurring during the study in the AE section of the CRF. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by [CONTACT_19448]'s condition.
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_21865] dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_10982].
If such values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified.
See Appendix 6 for suggested actions and follow-up assessments in the event of potential 
drug-induced liver injury.
8.2.6. Suicidal Ideation and Behavior Risk Monitoring - Columbia Suicide Severity 
Rating Scale (C-SSRS)
The C-SSRS is a validated tool for investigative staff to use to evaluate suicidal ideation and 
behavior.
14  At the Screening visit, per Exclusion Criterion # 2, if there is suicidal ideation 
associated with actual intent and/or plan in the past year, or previous history of suicidal 
behaviors in the past 5 years, the participant will not be included in the study.  Trained site staff is to administer the C-SSRS to all participants at Screening and assess the participant’s eligibility based on the answers.
[COMPANY_003]
PF-[ADDRESS_21866] 2020 
PFIZER CONFIDENTIAL
Page 76For participants meeting exclusionary results of the C-SSRS, it is recommended that the 
participant’s primary care physician (PCP) should be informed, and the participant referred to a mental health professional, either by [CONTACT_22834]. 
8.2.7. Local Tolerability Assessment
The investigator or designee will assess tolerability at the site of IP application (pre-dose and 
immediately post-dose).   
All participant reported and observed application site AEs should be 
recorded along with the body region location, severity, duration and outcome as indicated on the CRF. See Section 7.[ADDRESS_21867] 
25 mIU/mL.  Serum pregnancy tests are required at Screening visit only. Pregnancy tests will be performed in WOCBP at the times listed in the SoA.  Following a negative pregnancy 
test result at screening, appropriate contraception must be commenced and a second negative pregnancy test result will be required at the baseline visit prior the participant’s receiving the study intervention.  Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the end of the study.  Pregnancy tests may also be repeated if requested by [CONTACT_1202]/ECs or if required by [CONTACT_427].  
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy 
test is required.  In such cases, the participant must be excluded if the serum pregnancy result is positive.
Two negative pregnancy tests are required before randomization ([ADDRESS_21868] at Day 1 visit).
[COMPANY_003]CCI
CCI
PF-[ADDRESS_21869]
will be conducted, study intervention application paused and sponsor clinician and sponsor medical monitor notified immediately.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorized representative).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1 ). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, which is obtained before the participant’s participation in the study (ie, before undergoing any study-related procedure and/or receiving study intervention), through and including a 
minimum of [ADDRESS_21870] 2020 
PFIZER CONFIDENTIAL
Page 78Investigators are not obligated to actively seek AEs or SAEs after the participant has 
concluded study participation.  However, if the investigator learns of any SAE, including a death, at any time after a participant has completed the study, and he/she considers the event to be reasonably related to the study intervention, the investigator must promptly report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_21871] SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_21872] on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.
8.3.3. Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality.  Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety. 
Further information on follow-up procedures is given in Appendix [ADDRESS_21873] 2020 
PFIZER CONFIDENTIAL
Page 798.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by [CONTACT_22836] a study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation.  The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study intervention under study during pregnancy or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
•A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.
•A male participant who is receiving or has discontinued study intervention exposes a 
female partner prior to or around the time of conception.
•A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure.  Below are examples of environmental exposure during pregnancy:  
•A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by [CONTACT_22837].
•A male family member or healthcare provider who has been exposed to the study 
intervention by [CONTACT_22838].
[COMPANY_003]
PF-[ADDRESS_21874] report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy). 
•If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until [ADDRESS_21875] dose.
•If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless preprocedure test findings are conclusive for a congenital anomaly and the findings arereported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to [COMPANY_007] Safety as SAEs follows: 
•Spontaneous abortion including miscarriage and missed abortion;
•Neonatal deaths that occur within [ADDRESS_21876] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. 
Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner.  The investigator must document in the source documents that 
[COMPANY_003]
PF-[ADDRESS_21877] 2020 
PFIZER CONFIDENTIAL
Page 81the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
•A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention.
•A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study intervention by [CONTACT_19991].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE Report Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specifically
approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_22839], which may or may not lead to the occurrence of an AE.  Such persons 
may include healthcare providers, family members, and other roles that are involved in the trial participant’s care.
The investigator must report occupational exposure to [COMPANY_007] Safety within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE.  The information must be reported using the CT SAE Report Form.  Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
8.3.6. Cardiovascular and Death Events 
Not applicable.
[COMPANY_003]
PF-[ADDRESS_21878] 2020 
PFIZER CONFIDENTIAL
Page 828.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applicable.
[IP_ADDRESS]. Lack of Efficacy
Lack of efficacy is reportable to [COMPANY_007] Safety only if associated with an SAE.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Exposures to the study intervention under study may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
•Medication errors involving participant exposure to the study intervention;
•Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately within 
[ADDRESS_21879] 2020 
PFIZER CONFIDENTIAL
Page 83Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_21880] SAE Report 
Form only when associated with an SAE.
8.4. Treatment of Overdose
For this study, any dose of study intervention greater than one dose within a 12-hour time 
period will be considered an overdose.  
The maximum surface area of administration is 22% BSA for AD and 16.5% for psoriasis 
participants. Investigators should be aware that administration to significantly greater area may also be treated as an overdose at Investigator discretion.
The Sponsor does not recommend specific treatment for an overdose.In the event of an overdose, the investigator should:
1. Contact [CONTACT_22840] 24 hours.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least [ADDRESS_21881] 2020 
PFIZER CONFIDENTIAL
Page 868.9. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
[COMPANY_003]CCI
PF-[ADDRESS_21882]-randomization prohibited medication use will be imputed in the PF-07038124 arms using a copy to control method (ie, missing data in 0.01% QD regimen will be imputed from the distribution of participants on QD vehicle).  Participants with inadequate compliance will have their recorded EASI scores used as is in the analysis.  The population-based treatment effect will be the differences in the mean change from baseline in treatment arm compared to the vehicle. 
The secondary estimand will be the estimated population average treatment effect on the 
rates of IGA response (participants with a score of 0 or 1 and a 2 point or greater decrease from baseline) at Week [ADDRESS_21883] to compliance with IP in the absence of prohibited medication.  This is a composite estimand where success is defined as achievement of an IGA response as defined above while remaining on study, providing data and not taking prohibited medication; lack of compliance or adverse events will not be counted as a failure.  The population-based treatment effect will be the differences in the proportions of success in each treatment arm compared to the corresponding vehicle.  EASI 75 and other EASI scores will be treated in a similar manner.
All other secondary continuous clinical endpoints will be analyzed using the primary 
estimand, while all other secondary categorical clinical endpoints will be analyzed using the secondary estimand described above.  
  Other estimands may be used for some of the primary and 
secondary endpoints as a means to examine the robustness of the results and to compare to available literature as needed.  Details of these analyses will be presented in the Statistical Analysis Plan (SAP).
9.1.2. Estimands for Psoriasis
The primary estimand will be the population average treatment effect on change from 
baseline in PASI scores at Week [ADDRESS_21884] data imputed using a copy to control method (ie, missing data in 0.01% QD regimen will be imputed from the distribution of participants on QD vehicle) assuming these participants no longer receive an efficacy benefit from the IP but rather, have a response similar to participants assigned to vehicle. Participants with inadequate compliance will have their recorded PASI scores used as is in the analysis. The population-based treatment effect will be the differen ces in the mean change from baseline in 
each treatment arm compared to the corresponding vehicle. 
[COMPANY_003]CCI
PF-[ADDRESS_21885] on the PGA response 
rate (percentage of participants with a score of clear (0) or almost clear (1) and ≥[ADDRESS_21886] to compliance with IP in the absence of prohibited medication.  This is a composite estimand where success is defined as achievement of a PGA response while remaining on study, providing data and not taking prohibited medication; lack of compliance or adverse events will not be counted as a failure. The population-based treatment effect will be the differences in the proportions of successes in each treatment arm compared to the corresponding vehicle. 
All other key secondary continuous clinical endpoints will be analyzed using the primary 
estimand, while all other key secondary categorical clinical endpoints will be analyzed using the secondary estimand described above.   
  Other estimands may be used for some of the primary and 
secondary endpoints as a means to examine the robustness of the results and to compare to available literature as needed.  Details of these analyses will be presented in the SAP.
9.2. Sample Size Determination
9.2.1. Sample Size Determination for ADThe sample size calculation is based on the primary endpoint (percentage change from 
baseline in EASI score at Week 6). A total of 56 randomized participants in 1 treatment group and 1 vehicle group (28/arm) will provide approximately 90% power to detect a difference of [ADDRESS_21887] deviation 48% between PF-07038124 and a vehicle arm, controlling the two-sided error rate alpha 0.05. These calculations allow for a 25% dropout rate leaving 42 evaluable participants (21/arm).
For the key secondary endpoint, IGA response rate of clear or almost clear and ≥2 points 
improvement at Week 6, assuming 20% rate for vehicle and 55% rate for the treatment, this sample size provides 66% power controlling the two-sided error rate alpha 0.05.
9.2.2. Sample Size Determination for Psoriasis
The sample size is based on the primary efficacy endpoint, PASI change from baseline at 
Week 6. With an assumed standard deviation of 4.2 and treatment difference of 4.5, a total 
of 32 randomized participants in 2 treatment groups (16/arm) will provide approximately 
80% power for the comparison of active versus vehicle group at a two-sided significance of 0.1. This calculation allows for an approximate 25% dropout rate, that is 12 participants evaluable per arm at Week 6, where evaluable is defined as included in the mITT set (defined in Section 9.3 ).
For the key secondary endpoint, PGA response rate of clear or almost clear and ≥2 points 
improvement at Week 6, assuming 20% rate for vehicle and 65% rate for the treatment, this sample size provides 61.9% power controlling the two-sided error rate alpha 0.05.
[COMPANY_003]CCI
PF-[ADDRESS_21888] 2020 
PFIZER CONFIDENTIAL
Page 899.3. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Population Description
Safety Analysis Set All participants randomly assigned to IP and who apply at 
least [ADDRESS_21889] received.
Defined Population for AnalysisDescription
Modified Intention to 
Treat (mITT)All participants randomly assigned to IP and who apply at 
least 1 dose of IP.  
9.4. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data.  This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.4.1. Efficacy Analyses for AD
Endpoint Statistical Analysis Methods
Primary: 
Percent Change from Baseline EASI at Week 6A landmark analysis using analysis of covariance of percent change from 
baseline in EASI, adjusting for the baseline EASI score, to estimate the effect of the initially randomized treatment in the absence of prohibited medication regardless of treatment compliance.  The analysis will use the mITT analysis set.  Missing data due to any cause including censoring due to initiation of prohibited medication will be imputed using the corresponding vehicle arm, missing data in a vehicle arm will be imputed using data from the vehicle arm assuming data are missing at random (MAR).  The analysis will combine the results from the multiple imputations using Rubin’s rule as implemented in SAS PROC MIANALYZE.  
Secondary: IGA Response at Week 6A landmark analysis of the composite endpoint; achieving IGA without 
prohibited medication, while remaining on study and providing data.  Theanalysis will use the mITT analysis set.  Based on the definition of the composite endpoint all participants in the mITT set will have a response for all visits (ie, there is no missing data).  The proportions responding and 
[COMPANY_003]CCI
PF-[ADDRESS_21890] method; the risk differences and the corresponding 2-sided unconditional exact 90% confidence intervals will be computed using Chan and Zhang (1999)
16method.  
Other continuous secondary endpoints at time points specified in the SoA including change 
from baseline EASI, will be analyzed as described for the primary estimand along with descriptive statistics and possibly graphical displays.  
Other binary secondary endpoints at time points specified in the SoA including,  
EASI 75,  IGA of clear or almost clear will be analyzed as described for the secondary estimand along with descriptive statistics and possibly graphical displays.  
 
9.4.2. Efficacy Analyses for Psoriasis
Endpoint Statistical Analysis Methods
Primary: 
Change from Baseline PASI at Week 6A landmark analysis using analysis of covariance of change from baseline 
PASI, adjusting for the baseline PASI score, to estimate the effect of the initially randomized treatment in the absence of prohibited medication regardless of treatment compliance.  The analysis will use the mITT analysis set. Missing data due to any cause including censoring due to initiation of prohibited medication will be imputed using the corresponding vehicle arm, missing data in a vehicle arm will be imputed using data from the vehicle arm assuming data are missing at random (MAR).  The analysis will combine the results from the multiple imputations using Rubin’s rule as implemented in SAS PROC MIANALYZE.  
Secondary: PGA Response at Week 6A landmark analysis of the composite endpoint; achieving a PGA response 
(a score of clear (0) or almost clear (1) and ≥2 point improvement from 
baseline) without prohibited medication, while remaining on study and providing data. The analysis will use the mITT analysis set. Based on the definition of the composite endpoint all participants in the mITT set will have a response for all visits (ie, there is no missing data).  The proportions responding and the risk difference between treated arms and their corresponding vehicle control arm will be analyzed using an unconditional exact method: risk differences and corresponding 2-sidedunconditional exact 90% confidence intervals will be computed using the 
[COMPANY_003]CCI
CCI
CCI
CCI
PF-07038124
Protocol C3941002Final Protocol,19 August2020 
PFIZER CONFIDENTIAL
Page 91Endpoint Statistical Analysis Methods
Chan and Zhang (1999)16method. 
Other continuous secondary endpoints at time points specified in the SoAincluding: absolute 
PASI, change from baseline PASI, percent change frombaseline PASI, absolute and change from baseline Itch Severity Score, absolute and change from baseline Psoriasis Symptom Inventory will be analyzed as described for the primary estimand along with descriptive statistics and possibly graphical displays.  
Other binary secondary endpoints at time points specified in the SoAincluding,  
PASI75,  PGA of clear or almost clear will be analyzed as described for the secondary estimand along with descriptive statistics and possibly graphical displays.  
9.4.3. Safety Analyses
All safety analyses will be performedon the safety population.
Endpoint Statistical Analysis Methods
Primary The safety data will be summarized inaccordance with [COMPANY_007] Data 
Standards.  All participants who receive IP (safety population) will be included in the safetyanalyses.  All safety data will be summarized descriptively through appropriate datatabulations, descriptive statistics,categorical summaries, and graphical presentations.  Safetyendpoints for the study include:
Treatment-emergent AEs and SAEs;Withdrawals from active treatment due to AEs;Serious infections, defined as any infection (viral, bacterial, and fungal) 
requiringhospi[INVESTIGATOR_22769];
Safety laboratory tests (eg, hematology [including coagulation panel], 
chemistry andlipid profiles);
Vital signs.
Change from baseline on laboratory data and vital signs will be additionally 
summarized.  Participantlistings will also be produced for these safety endpoints.
[COMPANY_003]CCI
CCI
CCI
CCI
CCI
PF-[ADDRESS_21891] 2020 
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum postdose QTc values and maximum increases 
from baseline in the following categories will be tabulated by [CONTACT_3148]: 
Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, the number of participants with uncorrected QT values >500 msec will be
summarized.
9.5. Interim Analyses
No interim analyses are planned. 
9.6. Data Monitoring Committee or Other Independent Oversight Committee
This study will not use a Data Monitoring Committee (DMC).
[COMPANY_003]CCI
PF-[ADDRESS_21892] 2020 
PFIZER CONFIDENTIAL
Page 9310. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
•Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;
•Applicable ICH GCP guidelines;
•Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_22842]/EC by [CONTACT_22843]/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
The investigator will be responsible for the following:
•Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/EC;
•Notifying the IRB/EC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/EC procedures;
•Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_22844], or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, [COMPANY_007] should be informed immediately. 
In addition, the investigator will inform [COMPANY_007] immediately of any urgent safety measures 
taken by [CONTACT_22845], andof any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
[COMPANY_003]
PF-[ADDRESS_21893] 2020 
PFIZER CONFIDENTIAL
Page 9410.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study.  The participant should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC or study center.
The investigator must ensure that each study participant is fully informed about the nature 
and objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant’s personal data. 
The participant must be informed that his/her personal study-related data will be used by [CONTACT_20004]. The level of disclosure must also be explained to the participant.
The participant must be informed that his/her medical records may be examined by [CONTACT_11000], by [CONTACT_6667]/EC members, and by [CONTACT_6668].
The investigator further must ensure that each study is fully informed about his or her right to 
access and correct his or her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study.
A copy of the ICD(s) must be provided to the participant.Participants who are rescreened are required to sign a new ICD.
[COMPANY_003]
PF-[ADDRESS_21894] 2020 
PFIZER CONFIDENTIAL
Page 95Unless prohibited by [CONTACT_20006]/EC decision, the ICD will contain a separate 
section that addresses the use of samples for optional additional research. The optional additional research does not require the collection of any further samples.  The investigator or authorized designee will explain to each participant the objectives of the additionalresearch. Participants will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. A separate signature [CONTACT_22862] a participant's agreement to allow specimens to be used for additional research. Participants who decline to participate in this optional additional research will not provide this separate signature.
10.1.4. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only authorized study staff have access.  The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster.  In the event of a potential personal data breach, the study site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by [CONTACT_20007], participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to his or her actual identity and medical record identification. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local laws/regulations.  In addition, [COMPANY_007] reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.
[COMPANY_003]
PF-[ADDRESS_21895] 2020 
PFIZER CONFIDENTIAL
Page 96www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted.  These results are submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007]-sponsored interventional studies in 
accordance with the format and timelines set forth by [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure synopses (CSR synopses in which any data that could be used 
to identify individual participants have been removed) on www.pfizer.com for [COMPANY_007]-sponsored interventional studies at the same time the corresponding study results areposted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy 0070, the proactive publication of clinical 
data to the EMA website.  Clinical data, under Phase 1 of this policy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this policy, includes the publishing of individual participant data.  Policy 0070 applies to new marketing authorization applications submitted via the centralized procedure since 01 January 2015 and applications for line extensions and for new indications submitted via the centralized procedure since 01 July 2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient-level data or full CSRs for the purposes 
of “bona-fide scientific research” that contributes to the scientific understanding of the disease, target, or compound class. [COMPANY_007] will make available data from these trials [ADDRESS_21896], including individualsrequesting access for commercial/competitive or legal purposes.
[COMPANY_003]
PF-[ADDRESS_21897] 2020 
PFIZER CONFIDENTIAL
Page 9710.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries  are accurate and correct by [CONTACT_18027].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to prevent access by [CONTACT_20011].
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents.  This verification may also occur after study completion.  It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy (eg, risk-based initiatives in operations and quality 
such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring), are provided in the monitoring plan.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_21898] 2020 
PFIZER CONFIDENTIAL
Page 98The investigator(s) will notify the sponsor or its agents immediately of any regulatory
inspection notification in relation to the study.  Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection.  The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant's medical records.  The investigator will promptly provide copi[INVESTIGATOR_19946].  Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Definition of what constitutes source data can be found in the study monitoring plan.Description of the use of computerized system is documented in the Data Management Plan.10.1.8. Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor 
or designee/CRO if requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the health of study participants.
Reasons for the early closure of a study site by [CONTACT_19711]:
•Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
[COMPANY_003]
PF-[ADDRESS_21899] 2020 
PFIZER CONFIDENTIAL
Page 99•Inadequate recruitment of participants by [CONTACT_093];
•Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement.  If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study may be published or presented at scientific meetings by [CONTACT_22847] 1 year after the end of the study (or study termination), whichever comes first. 
The investigator agrees to refer to the primary publication in any subsequent publications 
such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor [ADDRESS_21900] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study is documented in the study contact [CONTACT_22848] (SToD) system. 
To facilitate access to appropriately qualified medical personnel on study-related medical 
questions or problems, participants are provided with a contact [CONTACT_22849].  The contact [CONTACT_4662], at a minimum, protocol and study interventionidentifiers, participant numbers, contact [CONTACT_22850], and contact [CONTACT_4664] a contact [CONTACT_22851] a medical question or problem originating from another healthcare professional not involved in the participant’s participation in the study.  The contact [CONTACT_22852]; however, it should be used only in the event that the established communication pathways between the investigator site and the study team are not available.  It is therefore intended to augment, but not replace, the established communication pathways between the investigator site and the study team for advice on medical questions or problems that may arise during the study.  The contact [CONTACT_22853], and if a participant calls that number, he or she will be directed back to the investigator site.
[COMPANY_003]
PF-[ADDRESS_21901] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values.  These additional tests would not require additional collection of blood.  Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 16. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count and indices 
(MCV, MCH
MCHC, RBC Morphology)Reticulocytes countWBC count with differential
Neutrophils (%, Abs)
Eosinophils (%, Abs)Monocytes (%, Abs)Basophils (%, Abs)Lymphocytes (%, Abs)Platelet countBUN/urea
CreatinineGlucose
Calcium
SodiumPotassiumChlorideTotal CO
2(bicarbonate)
Alanine transaminase 
(ALT)
Aspartate transaminase (AST)Total bilirubinDirect bilirubin
a
Alkaline phosphatase
Uric acid
AlbuminTotal proteinpH
Glucose (qual)Protein (qual)
Blood (qual)
KetonesNitritesLeukocyte esteraseUrobilinogenUrine bilirubin
Microscopy
bFSHc, e
Pregnancy test ( β-hCG)d
Fibrinogen
High-sensitivity C-reactive protein (hsCRP)
a. Only if total bilirubin is elevated.b. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.c. For confirmation of postmenopausal status, in females who are amenorrheic for at least [ADDRESS_21902] document their review of each laboratory safety report.
Laboratory/analyte results that could unblind the study will not be reported to investigator
sites or other blinded personnel until the study has been unblinded.
[COMPANY_003]CCI
PF-[ADDRESS_21903] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1. Definition of AE
AE Definition
•An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
•NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events Meeting the AE Definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator  Any abnormal laboratory test results that meet any of the conditions below must be recorded as an AE:
•Is associated with accompanying symptoms.
•Requires additional diagnostic testing or medical/surgical intervention.
•Leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy.
•Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.
[COMPANY_003]
PF-[ADDRESS_21904] 2020 
PFIZER CONFIDENTIAL
Page 103Events NOT Meeting the AE Definition
•Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_19448]’s condition.
•The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the participant’s condition.
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event thathypothetically might have caused death if it were more severe.
c. Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE 
[COMPANY_003]
PF-[ADDRESS_21905] 2020 
PFIZER CONFIDENTIAL
Page 104should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d. Results in persistent disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_22772]. These events should usually be considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.
•Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or non-pathogenic, is considered serious.  The event may be suspected from clinical symptoms or laboratory findings indicating an infection in a patient exposed to a [COMPANY_007] product.  The terms “suspected transmission” and “transmission” are considered synonymous .  These cases are considered unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also considered for reporting as product defects, if appropriate.
[COMPANY_003]
PF-[ADDRESS_21906] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].3.3. Recording/Reporting and Follow-up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safety. These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be completed in a consistent manner.  AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposureNone
All AEs/SAEs associated 
with exposure during pregnancy or breastfeeding
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)  
Note: Include all SAEs 
associated with exposure during pregnancy or breastfeeding. Include all AEs/SAEs associated with occupational exposure.
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.
•The investigator will then record all relevant AE/SAE information in the CRF.
•It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report Form/AE/SAE CRF page.
•There may be instances when copi[INVESTIGATOR_22773]
y. In this case, all participant identifiers, with the 
[COMPANY_003]
PF-[ADDRESS_21907] 2020 
PFIZER CONFIDENTIAL
Page 106exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories: 
•Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal
discomfort and not interfering with everyday activities.
•Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.
•Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
•The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.
•A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
•The investigator will use clinical judgment to determine the relationship.
•Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention administration, will be considered and investigated.
•The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
•For each AE/SAE, the investigator must document in the medical notes that he/she 
[COMPANY_003]
PF-[ADDRESS_21908] 2020 
PFIZER CONFIDENTIAL
Page 107has reviewed the AE/SAE and has provided an assessment of causality.
•There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor.
•The investigator may change his/her opi[INVESTIGATOR_9242]-up 
information and send an SAE follow-up report with the updated causality assessment.
•The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
•If the investigator does not know whether or not the study intervention caused the 
event, then the event will be handled as “related to study intervention” for reporting 
purposes, as defined by [CONTACT_456].  In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causalrelationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.
Follow-up of AEs and SAEs
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_22854]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare providers.
•New or updated information will be recorded in the originally completed CRF.
•The investigator will submit any updated SAE data to the sponsor within [ADDRESS_21909] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
•The primary mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
•If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
•The site will enter the SAE data into the electronic system as soon as the data
become available.
•After the study is completed at a given site, the electronic data collection tool will 
be taken off-line to prevent the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form (see next section) or to [COMPANY_007] Safety by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
•Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety.
•In circumstances when the facsimile is not working, notification by [CONTACT_20021] a copy of the CT SAE Report Form sent by [CONTACT_22855].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting time frames.
[COMPANY_003]
PF-[ADDRESS_21910] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].4. Appendix 4: Contraceptive Guidance 
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_21911] dose of study intervention, whichcorresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):
•Refrain from donating sperm.
PLUS either :
•Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
•Must agree to use a male condom when engaging in any activity that allows for 
passage of ejaculate to another person.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
•Is not a WOCBP (see definitions below in Section 10.4.3 ).
OR
•Is a WOCBP and using an acceptable contraceptive method as described below 
during the intervention period (for a minimum of [ADDRESS_21912] dose of study 
intervention).  The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be considered.
[COMPANY_003]
PF-[ADDRESS_21913] 2020 
PFIZER CONFIDENTIAL
Page 110Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:
•Documented hysterectomy;
•Documented bilateral salpi[INVESTIGATOR_1656];
•Documented bilateral oophorectomy.
For individuals with permanent infertility due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or medical history interview.  The method of documentation should be recorded in the participant’s medical record for the study.
2. Postmenopausal female:
•A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
•High FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
•Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study.  Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
10.4.4. Contraception Methods
Contraceptive use by [CONTACT_22856]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.3. Intrauterine hormone-releasing system.4. Bilateral tubal occlusion.
[COMPANY_003]
PF-[ADDRESS_21914] 2020 
PFIZER CONFIDENTIAL
Page 1115. Vasectomized partner:
•Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation:
•Oral;
•Intravaginal;
•Transdermal;
•Injectable.
7. Progestogen-only hormone contraception associated with inhibition of ovulation:
•Oral;
•Injectable.
8. Sexual abstinence:
•Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study intervention.  The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
9. Progestogen-only oral hormonal contraception where inhibition of ovulation is not the 
primary mode of action.
10. Male or female condom with or without spermicide.11. Cervical cap, diaphragm, or sponge with spermicide.12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double-barrier methods).
[COMPANY_003]
PF-[ADDRESS_21915] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury, but adapt are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a more serious potential outcome.  These participants fail to adapt and therefore are "susceptible" to progressive and serious liver injury, commonly referred to as DILI.  Participants who experience a transaminase elevation above 3
×ULN should be monitored 
more frequently to determine if they are an “adaptor” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) by [CONTACT_22857].  The increase in TBili typi[INVESTIGATOR_22774]/ALT is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be 
elevated within the same laboratory sample).  In rare instances, by [CONTACT_22858], AST/ALT values might have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
•Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently present with AST OR ALT values >3 × ULN AND a TBili value >2 × ULN with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not available.
•For participants with baseline AST ORALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
•Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 
×ULN; or >8 ×ULN (whichever is 
smaller).
•Preexisting values of TBili above the normal range: TBili level increased from 
baseline value by [CONTACT_8895] 1 × ULN orif the value reaches 
>3 × ULN (whichever is smaller).
[COMPANY_003]
PF-[ADDRESS_21916]/ALT and TBili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within [ADDRESS_21917] and ALT and TBili for suspected cases of 
Hy’s law, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase.  Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology.  A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated product in prescription or over-the-counter medications), recreational drug, supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary tract) and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.
[COMPANY_003]
PF-[ADDRESS_21918] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events
•Marked sinus bradycardia (rate <40 bpm) lasting minutes.
•New PR interval prolongation >280 msec.
•New prolongation of QTcF to >480 msec (absolute) or by ≥60 msec from baseline.
•New-onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie, rate <120 bpm.
•New-onset type I second-degree (Wenckebach) AV block of >30 seconds’ duration.
•Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive ventricular 
complexes.
ECG Findings That May Qualify as Serious Adverse Events
•QTcF prolongation >500 msec.
•New ST-T changes suggestive of myocardial ischemia.
•New-onset left bundle branch block (QRS >120 msec).
•New-onset right bundle branch block (QRS >120 msec).
•Symptomatic bradycardia.
•Asystole:
•In awake, symptom-free patients in sinus rhythm, with documented periods of 
asystole ≥3.0 seconds or any escape rate <40 bpm, or with an escape rhythm 
that is below the AV node; 
•In awake, symptom-free patients with atrial fibrillation and bradycardia with 
[ADDRESS_21919] 5 seconds or longer; 
•Atrial flutter or fibrillation, with rapi d ventricular response rate: rapid = rate 
>120 bpm.
•Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).
•Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm (heart 
rate <40 bpm), accelerated idioventricular rhythm (HR 40 bpm to <100 bpm), and 
[COMPANY_003]
PF-[ADDRESS_21920] 2020 
PFIZER CONFIDENTIAL
Page 116monomorphic/polymorphic ventricular tachycardia (HR >100 bpm (such as
torsades de pointes)).
•Type II second-degree (Mobitz II) AV block.
•Complete (third-degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
•Change in pattern suggestive of new myocardial infarction.
•Sustained ventricular tachyarrhythmias (>30 seconds’ duration).
•Second- or third-degree AV block requiring pacemaker placement.
•Asystolic pauses requiring pacemaker placement.
•Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
•Ventricular fibrillation/flutter.
•At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.
[COMPANY_003]
PF-[ADDRESS_21921] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8. Appendix 8: Country-Specific Requirements
Not applicable.
[COMPANY_003]
PF-[ADDRESS_21922] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9: Alternative Measures During Public Emergencies
The alternative study measures described in this section are to be followed during public 
emergencies, including the COVID-19 pandemic. This appendix applies for the duration of the COVID-19 pandemic globally and will become effective for other public emergencies only upon written notification from [COMPANY_007]. 
Use of these alternative study measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of any quarantines and travel bans/advisories). 
10.9.1. Telehealth Visits
In the event that in-clinic study visits cannot be conducted, every effort should be made to 
follow up on the safety of study participants at scheduled visits per the SoA or unscheduled 
visits. Telehealth visits may be used to continue to assess participant safety and collect data points where allowable by [CONTACT_22859]. Telehealth includes the exchange of healthcare information and services via telecommunication technologies (eg, audio, video, video-conferencing software) remotely, allowing the participant and the investigator to communicate on aspects of clinical care, including medical advice, reminders, education, and safety monitoring. The following assessments must be performed during a telehealth visit:
•Review and record study intervention(s), including compliance and missed doses.
•Review and record any  AEs and SAEs since the last contact.  Refer to Section 8.3 .
•Review and record any new concomitant medications or changes in concomitant 
medications since the last contact.
•Review and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the protocol. Refer to Appendix 4 and Section [IP_ADDRESS] of this appendix regarding 
pregnancy tests.
•Local Tolerability Assessments. 
•Efficacy Assessments (See Section 10.9.6 ).
Study participants must be reminded to promptly notify site staff about any change in their 
health status.
[COMPANY_003]
PF-[ADDRESS_21923] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9.2. Alternative Facilities for Safety Assessments
[IP_ADDRESS]. Laboratory TestingIf a study participant is unable to visit the site for protocol-specified safety laboratory 
evaluations, testing may be conducted at a local laboratory if permitted by [CONTACT_427].  The local laboratory may be a standalone institution or within a hospi[INVESTIGATOR_307]. The following safety laboratory evaluations may be performed at a local laboratory: 
•List safety laboratory evaluations, including pregnancy testing (See Table 16 Protocol 
Required Safety Laboratory Assessments).
If a local laboratory is used, qualified study site personnel must order, receive, and review 
results. Site staff must collect the local laboratory reference ranges and certifications/accreditations for filing at the site.  Laboratory test results are to be provided to the site staff as soon as possible.  The local laboratory reports should be  filed in the 
participant’s source documents/medical records. Relevant data from the local laboratory report should be  recorded on the CRF.  
If a participant requiring pregnancy testing cannot visit a local laboratory for pregnancy 
testing, a home urine pregnancy testing kit with a sensitivity of at least 25 mIU/mL may be used by [CONTACT_22860], if compliant with local regulatory requirements. The pregnancy test outcome should be documented in the participant’s source documents/medical records and relevant data recorded on the CRF. Confirm that the participant is adhering to the contraception method(s) required in the protocol. 
[IP_ADDRESS]. Electrocardiograms
If the participant is unable to visit the study site for ECGs, the participant may visit an 
alternative facility to have the ECGs performed. Qualified study site personnel must order, receive, and review results. 
A copy of the ECG should be available as source documents for review.10.9.3. Study Intervention
If the safety of a trial participant is at risk because they cannot complete required evaluations 
or adhere to critical mitigation steps, then discontinuing that participant from study intervention must be considered.
In situations where participants are quarantined or self-isolating, arrangements to send study 
intervention via courier may be implemented where allowable by [CONTACT_22861]’s verbal consent documented on the Provision of Critical Study Information Form (if applicable). The decision to supply requires the investigator to obtain and evaluate protocol-specified safety laboratory tests, pregnancy tests (for female subjects of childbearing potential), ECGs, contraception, concomitant treatment, and adverse events.
[COMPANY_003]
PF-[ADDRESS_21924] be kept in the participant’s source documents/medical records.
10.9.4. Home Health Visits
A home health care service may be utilized to facilitate scheduled visits per the Schedule of 
Activities .  Home health visits include a healthcare provider conducting an in-person study 
visit at the participant’s location, rather than an in-person study visit at the site. Home health visits may be implemented if it is not possible for participants to attend a study visits at the site and where allowable by [CONTACT_22859]. The following may be performed during a home health visit:
•Review and record study intervention(s), including compliance and missed doses.
•Review and record any  AEs and SAEs since the last contact.  Refer to Section 8.3 .
•Review and record any new concomitant medications or changes in concomitant 
medications since the last contact.
•Review and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the protocol. Refer to Appendix 4 and Section [IP_ADDRESS] of this appendix regarding 
pregnancy tests.
•ECG.
•Vital signs.
•Physical assessment.
•Laboratory sample, 
•Collect and weigh previous IP tubes.
•Dispensing of IP.
•IP application and observation.
•Local Tolerability Assessments. 
[COMPANY_003]CCI
PF-[ADDRESS_21925] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9.5. Adverse Events and Serious Adverse Events
If a participant has COVID-19 during the study, this should be reported as an adverse event 
(AE) or serious adverse events (SAE) and appropriate medical intervention provided. Temporary discontinuation of the study intervention may be medically appropriate until the participant has recovered from COVID-19 .
It is recommended that the investigator discuss temporary or permanent discontinuation of 
study intervention with the study medical monitor. 
10.9.6. Efficacy Assessments
If remote video visit is feasible and is being conducted as part of the Telehealth Visit in the 
event that in-clinic study visits cannot be conducted, the following procedures and assessments may be considered: 
•Efficacy Assessments for AD, including EASI, IGA, and BSA.
•Efficacy Assessments for psoriasis, including PASI, PGA and BSA.
Only qualified raters will be allowed to evaluate participants remotely.
10.9.7. Independent Oversight Committees
Not applicable.
[COMPANY_003]
PF-[ADDRESS_21926] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].10. Appendix 10: Prohibited Prior and Concomitant Medications
10.10.1. Prohibited Prior and Concomitant Medications
Drug Category Drugs (Examples below) Required Washout Period 
Requirement Prior to 
Day 1/Randomization
Any cell depleting 
agentsrituximab or other selective 
B-lymphocyte depleting agents (including experimental agents), alemtuzumab (Lemtrada
®or 
CamPath®), alkylating agents 
(eg, cyclophosphamide or 
chlorambucil), total lymphoid 
irradiation, etc.6 months or 5 half-lives (if known),
whichever is longer, or until lymphocyte count returns to normal, whichever is longer.
IL-17 inhibitor, IL-12/23 inhibitor, or IL-23 inhibitorsecukinumab (Cosentyx
®), ixekizumab 
(Taltz®), ustekinumab (Stelara®), 
brodalumab (Siliq®), guselkumab 
(Tremfya®), risankizumab (Skyrizi®),
tildrakizumab (Ilumya®), and 
bimekizumab,12 weeks.
TNF inhibitor adalimumab (Humira®or biosimilars),
certolizumab (Cimzia®), golimumab
(Simponi®and Simponi Aria®).10 weeks or 5 half-lives (whichever is 
longer) (Note: Infliximab (Remicade®or 
biosimilars) 8 weeks, Etanercept (Enbrel
®or biosimilars) 4 weeks).
Other biologics dupi[INVESTIGATOR_12458] (Dupi[INVESTIGATOR_12460]®), efalizumab 
(Raptiva®), abatacept (Orencia®).12 weeks unless otherwise specified in
this table.
Topi[INVESTIGATOR_22732]4
inhibitors (anywhere 
on the body), oral PDE4 inhibitorscrisaborole (Eucrisa
®), roflumilast
(Daliresp®, ARQ-151), apremilast 
(Otezla®).6w e e k s .
Systemic 
corticosteroids (oral, parenteral)4 weeks 
(stable use /regular regimen of intranasal/inhaled/ophthalmiccorticosteroids with ≥14 days of 
consistent use prior to 
Day 1/Randomization are permitted tocontinue but must not alter or stopregimen during the study).
Systemic immunosuppressive 
agents and other oral 
nonbiologic treatmentsmethotrexate, leflunomide, 
sulfasalazine, hydroxychloroquine, 
azathioprine, cyclosporine, mizoribine, 
tacrolimus, mycophenolate mofetil (MMF), hydroxycarbamide(hydroxyurea), fumaric acid derivatives, acitretin.4 weeks.
Oral JAK inhibitors tofacitinib (Xeljanz®), baricitinib 
(Olumiant®), upadacitinib, peficitinib, 
filgotinib.[ADDRESS_21927] 2020 
PFIZER CONFIDENTIAL
Page 123Drug Category Drugs (Examples below) Required Washout Period 
Requirement Prior to 
Day 1/Randomization
Interferon gamma interferon gamma-1b (Actimmune®). 4 weeks.
Light therapy etc. sunbathing, tanning bed use, or light 
therapy ultraviolet (UV), ultraviolet B(UV-B), psoralen-UV-A [PUVA]), excimer laser (308 nm).4 weeks.
Topi[INVESTIGATOR_22775],
Vitamin D analogues,benzoyl peroxide
(BPO), anthralin
(dithranol), keratolytics (salicylic acid), tars, on study treatable lesionstazarotene, calcipotriene. 2 weeks (stable regimen with ≥14 days 
of consistent use prior to Day 1/Randomization and not on the 
study treatable lesions are permitted to 
continue but must not alter or stop their regimen during the study.
Systemic antibiotics 2 weeks (Short courses ( ≤14 days) of 
systemic antibiotics may be given during 
the study if clinically necessary for the treatment of new onset infections).
Topi[INVESTIGATOR_11930] (TCS), class I to V, anywhere on the bodybetamethasone, clobetasol, diflorasone,
halobetasol, amcinonide, desoximetasone, fluocinonide, halcinonide, mometasone,
triamcinolone, clocortolone,
flurandrenolide, fluticasone,fluocinolone, prednicarbate,hydrocortisone butyrate, hydrocortisone probutate, hydrocortisone valerate.2 weeks.
Topi[INVESTIGATOR_22776] (TCI), 
anywhere on the bodytopi[INVESTIGATOR_22777] (Protopic
®), topi[INVESTIGATOR_22778] (Elidel®).2 weeks.
Topi[INVESTIGATOR_22779]. 2 weeks (topi[INVESTIGATOR_22780] 7 days of Day 1/Randomization). 
Topi[INVESTIGATOR_22781], including soaps, bleach baths, or topi[INVESTIGATOR_22782]-based 
products anywhere 
on the body7 days.
Systemic sedating 
antihistamineshydroxyzine, diphenhydramine, [ADDRESS_21928] 2020 
PFIZER CONFIDENTIAL
Page 124Drug Category Drugs (Examples below) Required Washout Period 
Requirement Prior to 
Day 1/Randomization
Systemic non-
sedating antihistamines in a nonstable (eg,escalating, decreasing, or PRN) regimencetirizine, 7 days (stable non-sedating systemic 
antihistamine regimen with ≥7d a y s  o f
consistent use prior to Day 1/Randomization are permitted to continue but must not alter or stop their regimen during the study).
Use of bland (non-medicated) emollients on treatable lesions24 hours (After the 
Day 1/Randomization Visit, use of bland (non-medicated) emollient(s) is permitted during the study to manage dry skin in areas surrounding but not on or 
overlappi[INVESTIGATOR_22783]).
Any other biologic investigational therapy for AD, psoriasis or psoriatic arthritis6 months unless otherwise specified in
this table.
Any other non-biological 
investigational
therapy or procedure for AD, psoriasis or psoriatic arthritis12 weeks unless otherwise specified in
this table.
Prohibited Concomitant Medications which 
may result in drug-
drug interaction See Section 10.10.2 below. 7 days or 5 half-lives (whichever is 
longer).
10.10.2. Prohibited Concomitant Medications which may result in Drug-Drug 
Interaction (DDI)  
Upon topi[INVESTIGATOR_22744]-07038124, systemic exposure to date has been low.  
Maximum plasma concentration has not exceeded 1 nM; which is approximately 1000-fold less than the IC
50values for CYP450 and UGT inhibition, as well as various transporters.  
Therefore, PF-07038124 has a low risk of any drug-drug interaction.  For more details, please refer to the Investigator’s Brochure.
[COMPANY_003]
PF-[ADDRESS_21929] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].11. Appendix 11: Diagnosis Criteria for AD
Per AD Specific Inclusion Criteria, a participant is to have a clinical diagnosis of AD
according to the criteria of Hanifin and Rajka.
Hanifin and Rajka’s Diagnostic Criteria for AD
Major Criteria (must have at least three)
Pruritus
Typi[INVESTIGATOR_22784]:
Flexural lichenification in adults
Facial and extensor eruptions in infants and children
Chronic or chronically-relapsing dermatitis
Personal or family history of atopy (asthma, allergic rhinitis, AD)
Minor Criteria (must have at least three)
Xerosis
Ichthyosis/keratosis pi[INVESTIGATOR_22785]/palmar hyperlinearity
Immediate (type 1) skin test reaction
Elevated serum IgE
Early age of onset
Tendency toward cutaneous infections (esp. staph. aureus and herpes simplex), impaired cell-mediated 
immunity
Tendency toward non-specific hand or foot dermatitis
Nipple eczema
Cheilitis
Recurrent conjunctivitis
Dennie-Morgan infraorbital fold
Keratoconus
Anterior subcapsular cataracts
Orbital darkening
Facial pallor, facial erythema
Pi[INVESTIGATOR_22786], delayed blanch
Hanifin J, Rajka G. Diagnostic features of atopic dermatitis Acta Derm Venereol. 1980;92:44.[ADDRESS_21930] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE].12. Appendix 12: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs A bsolute
AD Atopic Dermatitis
AE Adverse Event
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
AUC Area Under the Curve
AV Atrioventricular
β-hCG Beta-Human Chorionic Gonadotropin
BID Twice Daily
BLQ Below the Limit of Quantification
BMI Body Mass Index
bpm Beats Per Minute
BSA Body Surface Area
BUN Blood Urea Nitrogen
cAMP Cyclic Adenosine Monophosphate
Cav Avera ge Concentrations
CFR Code of Federal Regulations
cGMP Cyclic Guanosine Monophosphate
CIOMS Council for International Organizations of Medical Sciences
CK Creatine Kinase
Cmax Peak Plasma Concentrations
CO 2 Carbon Dioxide (Bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report Form
CRO Contract Research Organization
C-SSRS Columbia Suicide Severity Rating Scale
CSR Clinical Study Report
CT Clinical Trial
DCT Data Collection Tool
DDI Drug-Drug Interaction
DILI Dru g-Induced Liver In jury
DMC Data Moni toring Committee
DU Dispensable Unit
EASI Eczema Area and Severity Index
EC Ethics Committee
ECG Electrocardiogram
[COMPANY_003]CCI
CCI
CCI
PF-[ADDRESS_21931]
HR Heart Rate
HRT Hormone Replacement Therapy
hsCRP High-sensitivity C-reactive protein
IB Investigator’s Brochure
IC50 half maximal inhibitory concentration
ICD Informed Consent Document
ICH International Council for Harmonisation
ID Identification
IGA Investigator’s Global Assessment
IgE Immunoglobulin E
IL Interleukin
IMP Investigational Medicinal Product
IND Investigational New Drug
INR International Normalized Ratio
IP Investigational Product
IPAL Investigational Product Accountability Log
IRB Institutional Review Board
IRC Internal Review Committee
IRT Interactive Response Technology
IWR Interactive Web-Based Response
JAK Janus Kinase
LBBB Left Bundle Branch Block
LFT Liver Function Test
MCH Mean Corpuscular Hemoglobin
[COMPANY_003]
PF-[ADDRESS_21932] 2020 
PFIZER CONFIDENTIAL
Page 128Abbreviation Term
MCHC Mean Corpuscular Hemoglo bin Concentration
MCV Mean Cor puscular Volume
mITT Modified Intention to Treat 
MMF Mycophenolate Mofetil
MRHD Maximum Recommended Human Dose
msec Millisecond
N/A Not Applicable
NIMP Noninvestigational Medicinal Product
NOAEL No-Observed-Adverse-Effect Level
NOEL No Observed Effect Level
PASI Psoriasis Area and Severity Index
PBMC Peripheral Blood Mononuclear Cell
PD Pharmacodynamic(S)
PDE Phosphodiesterase
PDE4 phosphodiesterase 4
PFS Prefilled Syringe
PGA Ph ysician Global Assessment
PK Pharmacokinetic (S)
PP-NRS Peak Pruritus Numerical Rating Scale
PRO Patient Re ported Outcomes
PSI Psoriasis Symptom Inventory
PUVA Psoralen – Ultraviolet A
PVC Premature Ventricular Contraction/Complex
QD Once Daily
QoL Quality of Life
QTc Corrected QT
QTcF QTc Corrected Using Fridericia’s Formula
Qual Qualitative
Rac Accumulation Ratio
RBC Red Blood Cell
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SoA Schedule of Activities
SOP Standard Operating Procedure
SRSD Single Reference Safety Document
SToD Study Team on Demand
S[LOCATION_003]R Suspected Unex pected Serious Adverse Reaction
t½ terminal half-life 
[COMPANY_003]CCI
CCI
CCI
PF-[ADDRESS_21933] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. REFERENCES
1. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-22.
2. Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: 
psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. British Journal of Dermatology 2019; 181: 761-9
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. New England Journal of Medicine 2009; 
361: 496-509.
4. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic 
plaque psoriasis: a network meta ‐analysis. Cochrane Database of Systematic Reviews
2020; (1).
5. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a 
novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topi[INVESTIGATOR_22787] (AD) in children and adults. Journal of the American Academy of 
Dermatology 2016; 75: 494-503.e6.
6. Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of Roflumilast Cream for Chronic 
Plaque Psoriasis. New England Journal of Medicine 2020; 383: 229-39.
7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol
1980; 92: 44–7.
8. Tofte S, Graeber M, Cherill R, et al. Eczema area and severity index (EASI): A new 
tool to evaluate atopic dermatitis. Journal of the European Academy of Dermatology 
and Venereology 1998; 11: S197.
11. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. 
Dermatologica 1978; 157: 238-44.
12. Langley RGB, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global 
Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in 
clinical trials. Journal of Dermatological Treatment 2015; 26: 23-31.
[COMPANY_003]CCI
PF-[ADDRESS_21934] 2020 
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom 
Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. Journal of Dermatological Treatment 2013; 24: 356-60.
14. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: 
Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. American Journal of Psychiatry 2011; 168: 1266-77.
16. Chan ISF, Zhang Z. Test-Based Exact Confidence Intervals for the Difference of Two 
Binomial Proportions. Biometrics 1999; 55: 1202-9.
[COMPANY_003]CCI